<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="6718ba93-2693-44ba-93d2-8f873484a795"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ODEFSEY safely and effectively. See full prescribing information for ODEFSEY. <br/>
      <br/>ODEFSEY<sup>Â®</sup> (emtricitabine, rilpivirine, and tenofovir alafenamide) tablets, for oral use <br/>Initial U.S. Approval: 2016</title>
   <effectiveTime value="20250224"/>
   <setId root="ea3b9ec8-e04a-412c-8b3f-e5cbc7e641d5"/>
   <versionNumber value="12"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="185049848"/>
            <name>Gilead Sciences, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="c7e77d34-6719-442d-a8bc-cb60d8f49567"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250224"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="61958-2101" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ODEFSEY</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="200"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G70B4ETF4S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EMTRICITABINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="G70B4ETF4S" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EMTRICITABINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="212WAX8KDD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>RILPIVIRINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="FI96A8X663" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RILPIVIRINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator unit="mg" value="25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="FWF6Q91TZO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TENOFOVIR ALAFENAMIDE FUMARATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="W4HFE001U5" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TENOFOVIR ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="EL9943AG5J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TENOFOVIR ALAFENAMIDE</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61958-2101-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160301"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA208351" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160301"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48324" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="gray" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>capsule-shaped</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="15" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">GSI;255</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="dc174865-2e43-4770-a7fd-b01ca07cd3e5"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="emphasis">WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of ODEFSEY.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients with HIV-1 and HBV who discontinue ODEFSEY. If appropriate, anti-hepatitis B therapy may be warranted <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B</paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of ODEFSEY. Hepatic function should be monitored closely in these patients. If appropriate, anti-hepatitis B therapy may be warranted. (<linkHtml href="#S5.1">5.1</linkHtml>)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="d8fe0722-25d4-4cda-bcf2-9af014857230"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="90%" align="left" valign="top"/>
                           <col width="10%" align="left" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Indications and Usage (<linkHtml href="#S1">1</linkHtml>)</td>
                                 <td>02/2025</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#S2.2">2.2</linkHtml>)</td>
                                 <td>02/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="e819abaf-6d80-4d77-a854-262cdb13168b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">ODEFSEY is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 25 kg:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies/mL or</item>
                     <item>to replace a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies/mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of ODEFSEY <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ODEFSEY is a three-drug combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), and is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 25kg:</paragraph>
                        <list listType="unordered">
                           <item>as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies/mL; or</item>
                           <item>to replace a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies/mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of ODEFSEY. (<linkHtml href="#S1">1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Limitations of Use</content>:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>More rilpivirine-treated participants with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure (HIV-1 RNA â¥ 50 copies/mL) compared to rilpivirine-treated participants with HIV-1 RNA less than or equal to 100,000 copies/mL. (<linkHtml href="#S14.2">14.2</linkHtml>,<linkHtml href="#S14.3">14.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="49a1af92-44aa-43fc-9a95-7c60db58013d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Limitations of Use:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>More rilpivirine-treated participants with no antiretroviral treatment history with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure (HIV-1 RNA â¥ 50 copies/mL) compared to rilpivirine-treated participants with HIV-1 RNA less than or equal to 100,000 copies/mL <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2</linkHtml>,<linkHtml href="#S14.3">14.3)</linkHtml>].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="3c9c7e55-c03f-4730-ab96-5be6de383de1"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Testing: Prior to or when initiating ODEFSEY, test for hepatitis B virus infection. Prior to or when initiating ODEFSEY, and during treatment on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Recommended dosage: one tablet taken orally once daily with a meal. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>For pregnant patients who are already on ODEFSEY prior to pregnancy and who are virologically suppressed (HIV-1 RNA less than 50 copies per mL), one tablet taken once daily may be continued. Lower exposures of rilpivirine were observed during pregnancy, therefore viral load should be monitored closely. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                           <item>Renal impairment: ODEFSEY is not recommended in patients with estimated creatinine clearance of 15 to below 30 mL per minute, or below 15 mL per minute who are not receiving chronic hemodialysis. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="491af811-c0ec-47d2-8bde-540040862487"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Testing Prior to Initiation and During Treatment with ODEFSEY</title>
                     <text>
                        <paragraph>Prior to or when initiating ODEFSEY, test patients for hepatitis B virus infection <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Prior to or when initiating ODEFSEY, and during treatment with ODEFSEY, on a clinically appropriate schedule, assess  serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="00c82f5f-b562-4e27-93b5-b73dc38c7664"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Recommended Dosage in Adult and Pediatric Patients Weighing at Least 25 kg</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">ODEFSEY is a three-drug fixed dose combination product containing 200 mg of emtricitabine (FTC), 25 mg of rilpivirine (RPV), and 25 mg of tenofovir alafenamide (TAF). The recommended dosage of ODEFSEY is one tablet taken orally once daily with a meal in adults and pediatric patients with body weight at least 25 kg and creatinine clearance greater than or equal to 30 mL per minute <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="640b0e51-e067-4415-8845-806ecfc238d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Recommended Dosage During Pregnancy</title>
                     <text>
                        <paragraph>For pregnant patients who are already on ODEFSEY prior to pregnancy and are virologically suppressed (HIV-1 RNA less than 50 copies per mL), one tablet of ODEFSEY taken once daily may be continued. Lower exposures of rilpivirine, a component of ODEFSEY, were observed during pregnancy, therefore viral load should be monitored closely <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="82649093-0a13-42a5-a712-ed256c05e039"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Not Recommended in Patients with Severe Renal Impairment</title>
                     <text>
                        <paragraph>ODEFSEY is not recommended in patients with:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>severe renal impairment (estimated creatinine clearance of 15 to below 30 mL per minute); or</item>
                           <item>end stage renal disease (ESRD; estimated creatinine clearance below 15 mL per minute) who are not receiving chronic hemodialysis <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>, <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>, and <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="cf2515fb-23b7-4d5e-a1b7-cd19fd085be0"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Each ODEFSEY tablet contains 200 mg of emtricitabine (FTC), 25 mg of rilpivirine (RPV) (equivalent to 27.5 mg of rilpivirine hydrochloride), and 25 mg of tenofovir alafenamide (TAF) (equivalent to 28 mg of tenofovir alafenamide fumarate).</paragraph>
                  <paragraph>The tablets are gray, capsule-shaped, film-coated and debossed with "GSI" on one side and "255" on the other side.</paragraph>
               </text>
               <effectiveTime value="20250224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 200 mg of FTC, 25 mg of RPV and 25 mg of TAF. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="5e6dfd07-06c3-4dc8-baa4-96930013b794"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>ODEFSEY is contraindicated when coadministered with the following drugs; coadministration may result in loss of virologic response and possible resistance to ODEFSEY or to the class of NNRTIs <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin</item>
                     <item>Antimycobacterials: rifampin, rifapentine</item>
                     <item>Glucocorticoid (systemic): dexamethasone (more than a single-dose)</item>
                     <item>Herbal Products: St. John's wort <content styleCode="italics">(Hypericum perforatum)</content>
                     </item>
                     <item>Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole</item>
                  </list>
               </text>
               <effectiveTime value="20250224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ODEFSEY is contraindicated when coadministered with drugs where significant decreases in RPV plasma concentrations may occur, which may result in loss of virologic response and possible resistance and cross-resistance. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="0785722a-1621-4ba0-b5b2-814ac6d6745b"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Skin and Hypersensitivity Reactions: Severe skin and hypersensitivity reactions have been reported during postmarketing experience with RPV-containing regimens, including cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Immediately discontinue treatment if hypersensitivity or rash with systemic symptoms or elevations in hepatic serum biochemistries develops and closely monitor clinical status, including hepatic serum biochemistries. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>Hepatotoxicity: Hepatic adverse events have been reported in patients receiving an RPV-containing regimen. Monitor liver-associated tests before and during treatment with ODEFSEY in patients with underlying hepatic disease or marked elevations in liver-associated tests. Also consider monitoring liver-associated tests in patients without risk factors. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>Depressive disorders: Severe depressive disorders have been reported. Immediate medical evaluation is recommended for severe depressive disorders. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                           <item>New onset or worsening renal impairment: Assessment of serum creatinine, estimated creatinine clearance, urine glucose, and urine protein when initiating ODEFSEY and during therapy on a clinically appropriate schedule in all patients. Also assess serum phosphorus in patients with chronic kidney disease. (<linkHtml href="#S5.5">5.5</linkHtml>)</item>
                           <item>Concomitant use of ODEFSEY with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>Lactic acidosis/severe hepatomegaly with steatosis: Discontinue treatment in patients who develop symptoms or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity. (<linkHtml href="#S5.7">5.7</linkHtml>)</item>
                           <item>Immune reconstitution syndrome: May necessitate further evaluation and treatment. (<linkHtml href="#S5.8">5.8</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="ff1708e4-4f41-474b-90f8-9483b32e3389"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Severe Acute Exacerbation of Hepatitis B in Patients with HIV-1 and HBV</title>
                     <text>
                        <paragraph>Test patients with HIV-1 for the presence of hepatitis B virus (HBV) before or when initiating antiretroviral therapy <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Severe acute exacerbations of hepatitis B (e.g., liver decompensation and liver failure) have been reported in patients with HIV-1 and HBV who have discontinued products containing FTC and/or TDF, and may occur with discontinuation of ODEFSEY. Patients with HIV-1 and HBV who discontinue ODEFSEY should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment with ODEFSEY. If appropriate, anti-hepatitis B therapy may be warranted, especially in patients with advanced liver disease or cirrhosis, since post treatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="37dd84b2-c5ca-4680-93fb-a1da3ccdb601"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Skin and Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Severe skin and hypersensitivity reactions, including cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported during postmarketing experience with RPV-containing regimens. While some skin reactions were accompanied by constitutional symptoms such as fever, other skin reactions were associated with organ dysfunction, including elevations in hepatic serum biochemistries. During Phase 3 clinical trials of RPV, treatment-related rashes with at least Grade 2 severity were reported in 1% of participants. Overall, most rashes were Grade 1 or 2 and occurred in the first four to six weeks of therapy <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Discontinue ODEFSEY immediately if signs or symptoms of severe skin or hypersensitivity reactions develop, including but not limited to, severe rash or rash accompanied by fever, blisters, mucosal involvement, conjunctivitis, facial edema, angioedema, hepatitis, or eosinophilia. Clinical status including laboratory parameters should be monitored and appropriate therapy should be initiated.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="74f40c0c-8874-4754-9416-c5a8153b3de1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Hepatotoxicity</title>
                     <text>
                        <paragraph>Hepatic adverse events have been reported in patients receiving an RPV-containing regimen. Patients with underlying hepatitis B or C virus infection, or marked elevations in liver-associated tests prior to treatment, may be at increased risk for worsening or development of liver-associated test elevations with use of ODEFSEY. A few cases of hepatic toxicity have been reported in adult patients receiving an RPV-containing regimen who had no preexisting hepatic disease or other identifiable risk factors. Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with ODEFSEY is recommended in patients with underlying hepatic disease such as hepatitis B or C, or in patients with marked elevations in liver-associated tests prior to treatment initiation. Liver-associated test monitoring should also be considered for patients without preexisting hepatic dysfunction or other risk factors.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="8d417c21-051c-4fd7-91f2-418dbdde5120"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Depressive Disorders</title>
                     <text>
                        <paragraph>Depressive disorders (including depressed mood, depression, dysphoria, major depression, mood altered, negative thoughts, suicide attempt, suicidal ideation) have been reported with RPV. Promptly evaluate patients with severe depressive symptoms to assess whether the symptoms are related to ODEFSEY, and to determine whether the risks of continued therapy outweigh the benefits.</paragraph>
                        <paragraph>In Phase 3 trials of RPV in adult participants (N=1368) through 96 weeks, the incidence of depressive disorders (regardless of causality, severity) reported among RPV-treated participants (n=686) was 9%. Most events were mild or moderate in severity. In RPV-treated participants, the incidence of Grades 3 and 4 depressive disorders (regardless of causality) was 1%, the incidence of discontinuation due to depressive disorders was 1%, and suicidal ideation and suicide attempt was reported in 4 and 2 participants, respectively.</paragraph>
                        <paragraph>During the Phase 2 trial in RPV-treated pediatric participants 12 to less than 18 years of age (N=36), the incidence of depressive disorders (regardless of causality, severity) was 19% (7/36) through 48 weeks. Most events were mild or moderate in severity. The incidence of Grades 3 and 4 depressive disorders (regardless of causality) was 6% (2/36). None of the participants discontinued due to depressive disorders. Suicidal ideation and suicide attempt were reported in 1 participant.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="156101e9-12ac-4453-b69b-34338437b8f1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	New Onset or Worsening Renal Impairment </title>
                     <text>
                        <paragraph>Postmarketing case of renal impairment, including acute renal failure, proximal renal tubulopathy (PRT), and Fanconi syndrome have been reported with TAF-containing products; while most of these cases were characterized by potential confounders that may have contributed to the reported renal events, it is also possible these factors may have predisposed patients to tenofovir-related adverse events <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1</linkHtml>, <linkHtml href="#S6.2">6.2)</linkHtml>]</content>. ODEFSEY is not recommended in patients with estimated creatinine clearance of 15 to below 30 mL per minute, or in patients with estimated creatinine clearance below 15 mL per minute who are not receiving chronic hemodialysis.</paragraph>
                        <paragraph>Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents, including nonsteroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions.</paragraph>
                        <paragraph>Prior to or when initiating ODEFSEY, and during treatment with ODEFSEY, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus. Discontinue ODEFSEY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="780f00b2-b56c-4faa-954e-0a6b795d0340"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions</title>
                     <text>
                        <paragraph>The concomitant use of ODEFSEY and other drugs may result in potentially significant drug interactions, some of which may lead to <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, and <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Loss of therapeutic effect of ODEFSEY and possible development of resistance due to reduced exposure of RPV.</item>
                        </list>
                        <paragraph>In healthy participants, higher than recommended doses of RPV (75 mg once daily and 300 mg once daily â 3 and 12 times the recommended dosages in ODEFSEY, respectively) have been shown to prolong the QTc interval of the electrocardiogram. Consider alternatives to ODEFSEY when coadministered with a drug that is known to have a risk of Torsade de Pointes <content styleCode="italics">[see <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml> and <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>See <linkHtml href="#Tb3">Table 3</linkHtml> for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S7">Drug Interactions (7)</linkHtml>].</content> Consider the potential for drug interactions prior to and during ODEFSEY therapy and review concomitant medications during ODEFSEY therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="c6bcc826-e816-49dd-ac40-3882e59a9f70"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	Lactic Acidosis/Severe Hepatomegaly with Steatosis</title>
                     <text>
                        <paragraph>Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including emtricitabine, a component of ODEFSEY, and tenofovir DF, another prodrug of tenofovir, alone or in combination with other antiretrovirals. Treatment with ODEFSEY should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="f7b1980b-0464-4cf5-9416-7b8fcac8b470"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8	Immune Reconstitution Syndrome</title>
                     <text>
                        <paragraph>Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including FTC and RPV, both components of ODEFSEY. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as <content styleCode="italics">Mycobacterium avium</content> infection, cytomegalovirus, <content styleCode="italics">Pneumocystis jirovecii</content> pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.</paragraph>
                        <paragraph>Autoimmune disorders (such as Graves' disease, polymyositis, Guillain-BarrÃ© syndrome, and autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="4a98f132-7650-4a58-8241-19f6ab46ad1e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Severe Acute Exacerbations of Hepatitis B <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Skin and Hypersensitivity Reactions <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Depressive Disorders <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>New Onset or Worsening Renal Impairment <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>Lactic Acidosis/Severe Hepatomegaly with Steatosis <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>Immune Reconstitution Syndrome <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence greater than or equal to 2%, all grades) are headache and sleep disturbances. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="8bd262f9-799a-4c08-a3a4-5a795b4cc461"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug (or a drug given in various combinations with other concomitant therapy) cannot be directly compared to rates in the clinical trials of another drug (or drug given in the same or different combination therapy) and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                     <component>
                        <section>
                           <id root="9a7c25b7-d2ef-4235-9150-a16cc1379a6e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Clinical Trials of ODEFSEY in Virologically-Suppressed Adult Participants with HIV-1</content>
                              </paragraph>
                              <paragraph>The safety of ODEFSEY in virologically-suppressed adults is based on Week 48 data from two randomized, double-blinded, active-controlled clinical trials, 1160 and 1216, that enrolled 1505 adult participants with HIV-1 who were virologically-suppressed for at least 6 months. Both trials were designed to compare switching to ODEFSEY to maintaining efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) or emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) in Trials 1160 and 1216, respectively.  A total of 754 participants received one tablet of ODEFSEY daily <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>].</content>
                              </paragraph>
                              <paragraph>The most common adverse reactions (all Grades) reported in at least 2% of participants in the ODEFSEY group across Trials 1216 and 1160 were headache and sleep disturbances (Table 1).  Over 98% of the adverse reactions in the ODEFSEY group were of mild to moderate intensity.  The proportion of participants who discontinued treatment with ODEFSEY due to adverse events, regardless of severity, was 2% compared to 1% for FTC/RPV/TDF and 2% for EFV/FTC/TDF.</paragraph>
                              <table width="75%" ID="Tb1">
                                 <caption>Table 1 Adverse Reactions<footnote>Frequencies of adverse reactions are based on all adverse events attributed to study drugs by the investigator.</footnote> (All Grades) Reported in â¥1% of Virologically-Suppressed Adults with HIV-1 in Trial 1160 or Trial 1216 (Week 48 analysis)</caption>
                                 <col width="20%" align="left" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="2" align="center">Adverse Reaction</th>
                                       <th styleCode="Rrule" colspan="2">Trial 1160</th>
                                       <th styleCode="Rrule" colspan="2">Trial 1216</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule" align="center">ODEFSEY<br/>(N=438)</th>
                                       <th styleCode="Rrule">EFV/FTC/TDF <br/>(N=437)<footnote ID="t1fb">Data from Trials 1160 and 1216 do not provide an adequate basis for comparison of adverse reaction incidences between ODEFSEY and the FTC/RPV/TDF and EFV/FTC/TDF groups.</footnote>
                                       </th>
                                       <th styleCode="Rrule">ODEFSEY<br/>(N=316)</th>
                                       <th styleCode="Rrule">FTC/RPV/TDF<br/>(N=313)<footnoteRef IDREF="t1fb"/>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">1%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Sleep Disturbances</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">&lt;1%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Flatulence</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">&lt;1%</td>
                                       <td styleCode="Rrule">&lt;1%</td>
                                       <td styleCode="Rrule">1%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abnormal Dreams</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">1%</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250224"/>
                           <component>
                              <section>
                                 <id root="719b948c-df89-4ab4-83d3-ca76f49b204a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Renal Laboratory Tests</content>
                                    </paragraph>
                                    <paragraph>In Trial 1216, the median baseline eGFR was 104 mL per minute for participants who switched to ODEFSEY from FTC/RPV/TDF (N=316) and the mean serum creatinine decreased by 0.02 mg per dL from baseline to Week 48.</paragraph>
                                    <paragraph>In Trial 1160, the median baseline eGFR was 110 mL per minute for participants who switched to ODEFSEY from EFV/FTC/TDF (N=438), and the mean serum creatinine increased by 0.1 mg per dL from baseline to Week 48.</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="62e86bce-2a7a-428b-bf99-191ba61a58ba"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Bone Mineral Density Effects</content>
                                    </paragraph>
                                    <paragraph>Changes in BMD from baseline to Week 48 were assessed by dual-energy X-ray absorptiometry (DXA) in Trials 1216 and 1160.</paragraph>
                                    <paragraph>In Trial 1216, mean bone mineral density (BMD) increased in participants who switched to ODEFSEY (1.61% lumbar spine, 1.04% total hip) and remained stable or decreased in participants who remained on FTC/RPV/TDF (0.08% lumbar spine, â0.25% total hip). BMD declines of 5% or greater at the lumbar spine were experienced by 1.7% of ODEFSEY participants and 3.0% of FTC/RPV/TDF participants. BMD declines of 7% or greater at the femoral neck were experienced by 0% of ODEFSEY participants and 1.2% of FTC/RPV/TDF participants.</paragraph>
                                    <paragraph>In Trial 1160, mean BMD increased in participants who switched to ODEFSEY (1.65% lumbar spine, 1.28% total hip) and decreased slightly in participantswho remained on EFV/FTC/TDF (â0.05% lumbar spine, â0.13%  total hip). BMD declines of 5% or greater at the lumbar spine were experienced by 2.3% of ODEFSEY participants and 4.9% of EFV/FTC/TDF participants. BMD declines of 7% or greater at the femoral neck were experienced by 1.4% of ODEFSEY participants and 3.3% of EFV/FTC/TDF participants. The long-term clinical significance of these BMD changes is not known.</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="734fae4e-53fa-4a65-af05-cc1f381fcd6c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Serum Lipids</content>
                                    </paragraph>
                                    <paragraph>Changes from baseline in total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and total cholesterol to HDL ratio for Trials 1216 and 1160 are presented in Table 2.</paragraph>
                                    <table width="90%" ID="Table2">
                                       <caption>Table 2 Lipid Values, Mean Change from Baseline Reported in Participants Receiving ODEFSEY, FTC/RPV/TDF and EFV/FTC/TDF in Trials 1216 and 1160 at 48 Weeks</caption>
                                       <col width="13%" align="left" valign="middle"/>
                                       <col width="11%" align="center" valign="middle"/>
                                       <col width="11%" align="center" valign="middle"/>
                                       <col width="11%" align="center" valign="middle"/>
                                       <col width="11%" align="center" valign="middle"/>
                                       <col width="11%" align="center" valign="middle"/>
                                       <col width="11%" align="center" valign="middle"/>
                                       <col width="11%" align="center" valign="middle"/>
                                       <col width="10%" align="center" valign="middle"/>
                                       <thead>
                                          <tr styleCode="Botrule">
                                             <th styleCode="Lrule Rrule"/>
                                             <th colspan="4" styleCode="Rrule">Trial 1216</th>
                                             <th colspan="4" styleCode="Rrule">Trial 1160</th>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <th rowspan="3" styleCode="Lrule Rrule"/>
                                             <th colspan="2" styleCode="Rrule">ODEFSEY <br/>N=316<br/>[n=235]</th>
                                             <th colspan="2" styleCode="Rrule">FTC/RPV/TDF <br/>N=314<br/>[n=245]</th>
                                             <th colspan="2" styleCode="Rrule">ODEFSEY <br/>N=438<br/>[n=295]</th>
                                             <th colspan="2" styleCode="Rrule">EFV/FTC/TDF <br/>N=437<br/>[n=308]</th>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <th align="center" styleCode="Rrule">Baseline</th>
                                             <th styleCode="Rrule">Week 48</th>
                                             <th styleCode="Rrule">Baseline</th>
                                             <th styleCode="Rrule">Week 48</th>
                                             <th styleCode="Rrule">Baseline</th>
                                             <th styleCode="Rrule">Week 48</th>
                                             <th styleCode="Rrule">Baseline</th>
                                             <th styleCode="Rrule">Week 48</th>
                                          </tr>
                                          <tr>
                                             <th align="center" styleCode="Rrule">mg/dL</th>
                                             <th styleCode="Rrule">Change<footnote ID="T2F1">The change from baseline is the mean of within-participant changes from baseline for participants with both baseline and Week 48 values.</footnote>
                                                <sup>,</sup>
                                                <footnote ID="T2F2">Participants who received lipid-lowering agents during the treatment period were excluded.</footnote>
                                             </th>
                                             <th styleCode="Rrule">mg/dL</th>
                                             <th styleCode="Rrule">Change<footnoteRef IDREF="T2F1"/>
                                                <sup>,</sup>
                                                <footnoteRef IDREF="T2F2"/>
                                             </th>
                                             <th styleCode="Rrule">mg/dL</th>
                                             <th styleCode="Rrule">Change<footnoteRef IDREF="T2F1"/>
                                                <sup>,</sup>
                                                <footnoteRef IDREF="T2F2"/>
                                             </th>
                                             <th styleCode="Rrule">mg/dL</th>
                                             <th styleCode="Rrule">Change<footnoteRef IDREF="T2F1"/>
                                                <sup>,</sup>
                                                <footnoteRef IDREF="T2F2"/>
                                             </th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Total Cholesterol (fasted)</td>
                                             <td styleCode="Rrule">176</td>
                                             <td styleCode="Rrule">+17</td>
                                             <td styleCode="Rrule">171</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">193</td>
                                             <td styleCode="Rrule">-7</td>
                                             <td styleCode="Rrule">192</td>
                                             <td styleCode="Rrule">-3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">HDL-Cholesterol (fasted)</td>
                                             <td styleCode="Rrule">50</td>
                                             <td styleCode="Rrule">+3</td>
                                             <td styleCode="Rrule">48</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">56</td>
                                             <td styleCode="Rrule">-4</td>
                                             <td styleCode="Rrule">55</td>
                                             <td styleCode="Rrule">-2</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">LDL-Cholesterol (fasted)</td>
                                             <td styleCode="Rrule">111</td>
                                             <td styleCode="Rrule">+13</td>
                                             <td styleCode="Rrule">108</td>
                                             <td styleCode="Rrule">+1</td>
                                             <td styleCode="Rrule">118<footnote ID="t2fc">[n=296] for ODEFSEY group in Study 1160 for LDL-Cholesterol (fasted)</footnote>
                                             </td>
                                             <td styleCode="Rrule">-1<footnoteRef IDREF="t2fc"/>
                                             </td>
                                             <td styleCode="Rrule">119</td>
                                             <td styleCode="Rrule">-1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Triglycerides (fasted)</td>
                                             <td styleCode="Rrule">
                                                <br/>116</td>
                                             <td styleCode="Rrule">+12</td>
                                             <td styleCode="Rrule">119</td>
                                             <td styleCode="Rrule">-9</td>
                                             <td styleCode="Rrule">139</td>
                                             <td styleCode="Rrule">-12</td>
                                             <td styleCode="Rrule">133</td>
                                             <td styleCode="Rrule">+3</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Total Cholesterol to HDL Ratio</td>
                                             <td styleCode="Rrule">3.7</td>
                                             <td styleCode="Rrule">+0.2</td>
                                             <td styleCode="Rrule">3.8</td>
                                             <td styleCode="Rrule">+0.1</td>
                                             <td styleCode="Rrule">3.7</td>
                                             <td styleCode="Rrule">+0.2</td>
                                             <td styleCode="Rrule">3.8</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8a2e544a-c17a-49ed-b371-dcd9b788b1e9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Clinical Trials of RPV-Containing Regimens in Treatment-NaÃ¯ve Adult Participants with HIV-1</content>
                              </paragraph>
                              <paragraph>In pooled 96-week trials of antiretroviral treatment-naÃ¯ve adult participants with HIV-1, the most common adverse reactions in participantstreated with RPV+FTC/TDF (N=550) (incidence greater than or equal to 2%, Grades 2â4) were headache, depressive disorders, and insomnia. The proportion of participants who discontinued treatment with RPV+FTC/TDF due to adverse reactions, regardless of severity, was 2%. The most common adverse reactions that led to discontinuation in this treatment group were psychiatric disorders (1.6%) and rash (0.2%). Although the safety profile was similar in virologically-suppressed adults with HIV-1 who were switched to RPV and other antiretroviral drugs, the frequency of adverse events increased by 20% (N=317).</paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                           <component>
                              <section>
                                 <id root="2d024ac2-bb63-414b-9c4a-6bec5760b4c8"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Adrenal Function</content>
                                    </paragraph>
                                    <paragraph>In the pooled Phase 3 trials, at Week 96, there was an overall mean change from baseline in basal cortisol of -0.69 (-1.12, 0.27) micrograms/dL in the RPV group and of -0.02 (-0.48, 0.44) micrograms/dL in the EFV group.</paragraph>
                                    <paragraph>In the RPV group, 43/588 (7%) of participants with a normal 250 micrograms ACTH stimulation test at baseline developed an abnormal 250 micrograms ACTH stimulation test (peak cortisol level &lt;18.1 micrograms/dL) during the trial compared to 18/561 (3%) in the EFV group. Of the participants who developed an abnormal 250 micrograms ACTH stimulation test during the trial, 14 participants in the RPV group and 9 participants in the EFV group had an abnormal 250 micrograms ACTH stimulation test at Week 96. Overall, there were no serious adverse events, deaths, or treatment discontinuations that could clearly be attributed to adrenal insufficiency. The clinical significance of the higher abnormal rate of 250 micrograms ACTH stimulation tests in the RPV group is not known.</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="de8d5da4-ecde-4fcc-8bbe-4c82766c1331"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Clinical Trials of FTC+TAF with EVG+COBI in Treatment-NaÃ¯ve Adult Participants with HIV-1</content>
                              </paragraph>
                              <paragraph>In pooled 48-week trials of antiretroviral treatment-naÃ¯ve adult participants with HIV-1, the most common adverse reaction in participants treated with FTC+TAF with EVG+COBI (N=866) (incidence greater than or equal to 10%, all grades) was nausea (10%). In this treatment group, 0.9% of participants discontinued FTC+TAF with EVG+COBI due to adverse event <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. Antiretroviral treatment-naÃ¯ve adult participants treated with FTC+TAF with EVG+COBI experienced mean increases of 30 mg/dL of total cholesterol, 15 mg/dL of LDL cholesterol, 7 mg/dL of HDL cholesterol and 29 mg/dL of triglycerides after 48 weeks of use.</paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                           <component>
                              <section>
                                 <id root="3a7af34c-ec47-474f-8ca7-f1139fed310b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Renal Laboratory Tests</content>
                                    </paragraph>
                                    <paragraph>In two 48-week trials in antiretroviral treatment-naÃ¯ve adults with HIV-1 treated with FTC+TAF with elvitegravir (EVG) plus cobicistat (COBI) (N=866) with a median baseline eGFR of 115 mL per minute, mean serum creatinine increased by 0.1 mg per dL from baseline to Week 48.</paragraph>
                                    <paragraph>In clinical trials of FTC+TAF with EVG+COBI in treatment-naÃ¯ve participants and in virologically-suppressed participants switched to FTC+TAF with EVG+COBI with estimated creatinine clearance greater than 50 mL per minute, renal serious adverse events or discontinuations due to renal adverse reactions were encountered in less than 1% of participants treated with FTC+TAF with EVG+COBI.</paragraph>
                                    <paragraph>In a 24-week trial in adults with renal impairment (baseline eGFR 30 to 69 mL per minute) who received FTC+TAF with EVG+COBI (N=248), mean serum creatinine was 1.5 mg per dL at both baseline and Week 24. FTC+TAF with EVG+COBI was permanently discontinued due to worsening renal function in two of 80 (3%) participants.</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="9a6d49a7-6dab-47f4-80cc-6be77edc8b55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Bone Mineral Density Effects</content>
                                    </paragraph>
                                    <paragraph>In the pooled analysis of two 48-week trials of antiretroviral treatment-naÃ¯ve adult participants with HIV-1, bone mineral density (BMD) from baseline to Week 48 was assessed by dual-energy X-ray absorptiometry (DXA). Mean BMD decreased from baseline to Week 48 by -1.30% with FTC+TAF with EVG+COBI at the lumbar spine and -0.66% at the total hip. BMD declines of 5% or greater at the lumbar spine were experienced by 10% of FTC+TAF with EVG+COBI participants. BMD declines of 7% or greater at the femoral neck were experienced by 7% of FTC+TAF with EVG+COBI participants. The long-term clinical significance of these BMD changes is not known.</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4ed245c7-c1c4-469d-8cb1-2202f71fd1bb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline"> Adverse Reactions in Clinical Trials in Pediatric Participants with HIV-1</content>
                              </paragraph>
                              <paragraph>In an open-label 48-week trial (TMC278-C213 Cohort 1) of 36 antiretroviral treatment-naÃ¯ve pediatric participants with HIV-1 aged 12 to less than 18 years (weighing at least 32 kg) treated with 25 mg per day of RPV and other antiretrovirals, the most common adverse reactions were headache (19%), depression (19%), somnolence (14%), nausea (11%), dizziness (8%), abdominal pain (8%), vomiting (6%) and rash (6%).</paragraph>
                              <paragraph>In an open-label 48-week trial (TMC278-C213 Cohort 2) of 18 antiretroviral treatment-naÃ¯ve pediatric participants with HIV-1  aged 6 to less than 12 years (weighing at least 17 kg) treated with RPV and other antiretrovirals, the most common adverse reactions were decreased appetite (17%), vomiting (11%), ALT increased (11%), AST increased (11%), and rash (11%).</paragraph>
                              <paragraph>In an open-label 48-week trial (TMC278HTX2002) of 26 virologically suppressed participants with HIV-1 less than 12 years of age (weighing at least 16 kg) treated with RPV and other antiretrovirals, the most commen adverse reactions were vomiting (15%), abdominal pain (12%), nausea (8%), ALT increased (12%), AST increased (8%), and decreased appetite (8%).</paragraph>
                              <paragraph>In a 48-week, open-label trial, 50 antiretroviral treatment-naÃ¯ve pediatric participants with HIV-1 aged 12 to less than 18 years and weighing at least 35 kg (Cohort 1) and 52 virologically-suppressed pediatric participants aged 6 to less than 12 years and weighing at least 25 kg (Cohort 2) received FTC+TAF with EVG+COBI. With the exception of a decrease in the mean CD4+ cell count observed in Cohort 2 of this study, the safety profile in pediatric participants who received this combination was similar to that in adults.</paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                           <component>
                              <section>
                                 <id root="955bb6c9-f976-4179-93f7-76c423393f6b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Bone Mineral Density Effects</content>
                                    </paragraph>
                                    <paragraph>Among the pediatric participants in Cohort 1 receiving FTC+TAF with EVG+COBI, mean BMD increased from baseline to Week 48, +4.2% at the lumbar spine and +1.3% for the total body less head (TBLH). Mean changes from baseline BMD Z-scores were -0.07 for lumbar spine and -0.20 for TBLH at Week 48. In cohort 1, one participant had significant (at least 4%) lumbar spine BMD loss at Week 48.</paragraph>
                                    <paragraph>Among the pediatric participants in Cohort 2 receiving FTC+TAF with EVG+COBI, mean BMD increased from baseline to Week 48, +3.9% at the lumbar spine and +4.2% for TBLH. Mean changes from baseline BMD Z-scores were -0.24 for lumbar spine and -0.19 for TBLH at Week 48. In Cohort 2, six participants had significant (at least 4%) lumbar spine BMD loss at Week 48; 2 participants also had at least 4% TBLH BMD loss at Week 48.</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2e395387-7c77-4c67-a047-b15897f86175"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Change from Baseline in CD4+ Cell Counts</content>
                                    </paragraph>
                                    <paragraph>Although all participants in Cohort 2 receiving FTC+TAF with EVG+COBI had HIV-1 RNA &lt; 50 copies/mL, there was a decrease from baseline in CD4+ cell count at Weeks 24 and 48. The mean baseline and mean change from baseline in CD4+ cell count and in CD4% from Week 2 to Week 48 are presented in Table 3. All participants maintained their CD4+ cell counts above 400 cells/mm<sup>3</sup>
                                       <content styleCode="italics"> [see <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml> and <linkHtml href="#S14.3">Clinical Studies (14.3)</linkHtml>].</content>
                                    </paragraph>
                                    <table width="85%" ID="Tb3">
                                       <caption>Table 3	Mean Change in CD4+ Count and CD4 Percentage from Baseline to Week 48 in Virologically-Suppressed Pediatric Patients from 6 to &lt;12 Years Who Switched to FTC+TAF with EVG+COBI</caption>
                                       <col width="14%" align="left" valign="top"/>
                                       <col width="14%" align="left" valign="top"/>
                                       <col width="12%" align="left" valign="top"/>
                                       <col width="12%" align="left" valign="top"/>
                                       <col width="12%" align="left" valign="top"/>
                                       <col width="12%" align="left" valign="top"/>
                                       <col width="12%" align="left" valign="top"/>
                                       <col width="12%" align="left" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule"/>
                                             <th styleCode="Rrule"/>
                                             <th colspan="6" align="center" styleCode="Rrule Botrule">Mean Change from Baseline</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Lrule Rrule"/>
                                             <th styleCode="Rrule">Baseline</th>
                                             <th styleCode="Rrule">Week 2</th>
                                             <th styleCode="Rrule">Week 4</th>
                                             <th styleCode="Rrule">Week 12</th>
                                             <th styleCode="Rrule">Week 24</th>
                                             <th styleCode="Rrule">Week 32</th>
                                             <th styleCode="Rrule">Week 48</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">CD4+ Cell Count (cells/mm<sup>3</sup>)</td>
                                             <td styleCode="Rrule">961 (275.5)<footnote ID="Tb3ft">Mean (SD)</footnote>
                                             </td>
                                             <td styleCode="Rrule">-117</td>
                                             <td styleCode="Rrule">-114</td>
                                             <td styleCode="Rrule">-112</td>
                                             <td styleCode="Rrule">-118</td>
                                             <td styleCode="Rrule">-62</td>
                                             <td styleCode="Rrule">-66</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">CD4%</td>
                                             <td styleCode="Rrule">38 (6.4)<footnoteRef IDREF="Tb3ft"/>
                                             </td>
                                             <td styleCode="Rrule">+0.3%</td>
                                             <td styleCode="Rrule">-0.1%</td>
                                             <td styleCode="Rrule">-0.8%</td>
                                             <td styleCode="Rrule">-0.8%</td>
                                             <td styleCode="Rrule">-1.0%</td>
                                             <td styleCode="Rrule">-0.6%</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="eb1a8b1e-3555-4006-bd69-af76a0af688d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Adrenal Function in Clinical Trials of RPV in Pediatric Participants</content>
                              </paragraph>
                              <paragraph>In trial TMC278-C213 Cohort 1, at Week 48, the overall mean change from baseline in basal cortisol showed an increase of 1.59 (0.24, 2.93) micrograms/dL.</paragraph>
                              <paragraph>Six of 30 (20%) participants with a normal 250 micrograms ACTH stimulation test at baseline developed an abnormal 250 micrograms ACTH stimulation test (peak cortisol level &lt;18.1 micrograms/dL) during the trial. Three of these participants had an abnormal 250 micrograms ACTH stimulation test at Week 48. Overall, there were no serious adverse events, deaths, or treatment discontinuations that could clearly be attributed to adrenal insufficiency. The clinical significance of the abnormal 250 micrograms ACTH stimulation tests is not known.</paragraph>
                              <paragraph>In trial TMC278-C213 Cohort 2, basal cortisol at baseline was normal (â¥9 Î¼g/dL) for 4/18 participants, low for 13/18 participants, and missing for 1/18 participants.</paragraph>
                              <paragraph>Among the 4 participants with normal basal cortisol at baseline, 3 participants had either normal basal cortisol levels (â¥9 Î¼g/dL) or normal cortisol levels 1 hour after ACTH stimulation (â¥18.1 Î¼g/dL) throughout the trial and/or at the last available visit (Week 24 and Week 72), and 1 participant had low basal cortisol at the last available assessment (Week 48) and no ACTH stimulation test was performed. Among the 13 participants with low basal cortisol pre-dose at baseline, 2 participants had low basal and ACTH stimulated cortisol values throughout the trial, including ACTH stimulated cortisol at baseline before starting treatment with RPV. For both participants, no adverse events suggestive for adrenal insufficiency were reported. The remaining 11 participants had normal serum cortisol values after ACTH stimulation at baseline and/or during treatment.</paragraph>
                              <paragraph>In trial TMC278HTX2002, 15/26 participants had either normal basal cortisol (â¥9 Î¼g/dL) or normal cortisol 1 hour after ACTH stimulation (â¥18.1 Î¼g/dL), 9 had low basal cortisol on Day 1, and in 2 participants the baseline value was missing.</paragraph>
                              <paragraph>From the 19 participants with low basal cortisol at Week 48, in 15 participants, the Week 48 serum cortisol levels returned to normal (â¥248 nmol/L) after repeat serum basal cortisol testing or was normal after ACTH stimulation testing (â¥500 nmol/L). In 4 participants, the serum cortisol levels remained low after repeat serum basal cortisol testing or after ACTH stimulation testing. At Week 48, 6 participants had normal (basal) cortisol (â¥9 ug/dL) and the Week 48 result was not available for 1 participant.</paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="fa8eacd6-d195-4134-bd22-c93cd7f5583d"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postmarketing experience in patients receiving RPV or TAF-containing regimens. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                     <component>
                        <section>
                           <id root="350c41fb-1cd5-4351-abd1-3080afe3484d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Rilpivirine:</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                           <component>
                              <section>
                                 <id root="58a90d4c-d13e-4139-bccd-bc97072cc59a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Metabolism and Nutrition Disorders</content>
                                    </paragraph>
                                    <paragraph>Weight increased</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3256a411-e6b2-4b04-90b0-35c164bcb92a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Skin and Subcutaneous Tissue Disorders</content>
                                    </paragraph>
                                    <paragraph>Severe skin and hypersensitivity reactions including DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms)</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="e9976c6a-3f7b-4237-8ebe-ca668146c837"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Renal and Urinary Disorders</content>
                                    </paragraph>
                                    <paragraph>Nephrotic syndrome</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d45642cc-3c73-49fa-b63f-f3f07dd2ab5c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Tenofovir alafenamide:</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                           <component>
                              <section>
                                 <id root="1d74cb8e-1858-4fcc-a23b-58fb8a4e0d32"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Skin and Subcutaneous Tissue Disorders</content>
                                    </paragraph>
                                    <paragraph>Angioedema, urticaria, and rash</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="d4ee544a-608d-4991-8c26-c6d0e46d9649"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Renal and Urinary Disorders</content>
                                    </paragraph>
                                    <paragraph>Acute renal failure, acute tubular necrosis, proximal renal tubulopathy, and Fanconi syndrome</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="bf9d9e46-de29-4c05-9b26-085bb8aef0c9"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.6">5.6</linkHtml>, <linkHtml href="#S7">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="327df59d-011c-4b81-ac60-9863a16480c7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Not Recommended with Other Antiretroviral Medications</title>
                     <text>
                        <paragraph>Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="150ab31e-20ef-4bb3-9f3e-c1f7053493a1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 	Drugs Inducing or Inhibiting CYP3A Enzymes</title>
                     <text>
                        <paragraph>RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>, and <linkHtml href="#Tb4">Table 4</linkHtml>]</content>.</paragraph>
                        <paragraph>Coadministration of RPV and drugs that inhibit CYP3A may result in increased plasma concentrations of RPV and possible adverse events.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="8d8f0f89-1641-4644-b971-455e2e7fcef6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 	Drugs Inducing or Inhibiting P-glycoprotein</title>
                     <text>
                        <paragraph>TAF, a component of ODEFSEY, is a substrate of P-gp, BCRP, OATP1B1, and OATP1B3. Drugs that strongly affect P-gp and BCRP activity may lead to changes in TAF absorption <content styleCode="italics">(see <linkHtml href="#Tb4">Table 4</linkHtml>)</content>. Drugs that induce P-gp activity are expected to decrease the absorption of TAF, resulting in decreased plasma concentration of TAF, which may lead to loss of therapeutic effect of ODEFSEY and development of resistance. Coadministration of ODEFSEY with other drugs that inhibit P-gp and BCRP may increase the absorption and plasma concentration of TAF.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.4">
                     <id root="63dedc6a-1d75-4e3c-b46e-7178f1f3ec9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 	Drugs Increasing Gastric pH</title>
                     <text>
                        <paragraph>Coadministration of RPV with drugs that increase gastric pH  may decrease plasma concentrations of RPV and lead to loss of virologic response and possible resistance to RPV or to the class of NNRTIs. Use of RPV with proton pump inhibitors is contraindicated and use of RPV with H<sub>2</sub>-receptor antagonists requires staggered administration <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#Tb4">Table 4</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.5">
                     <id root="885b4099-d7b3-438a-a619-c722b5783c17"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5	QT Prolonging Drugs</title>
                     <text>
                        <paragraph>There is limited information available on the potential for a pharmacodynamic interaction between RPV and drugs that prolong the QTc interval. In a study of healthy participants, higher than recommended doses of RPV, 75 mg once daily and 300 mg once daily (3 times and 12 times recommended daily dose in ODEFSEY) prolonged the QTc interval <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml> and <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>. Consider alternative medications to ODEFSEY in patients taking a drug with a known risk of Torsade de Pointes.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.6">
                     <id root="5ceb97f6-6127-46b2-abfe-e58a4457166e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6	Drugs Affecting Renal Function</title>
                     <text>
                        <paragraph>Because FTC and tenofovir are primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion, coadministration of ODEFSEY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of FTC, tenofovir, and other renally eliminated drugs and this may increase the risk of adverse reactions. Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.7">
                     <id root="40a3d467-8275-4475-97b3-11c902bfeeb5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.7	Significant Drug Interactions</title>
                     <text>
                        <paragraph>Table 4 provides a listing of established or potentially clinically significant drug interactions with recommended steps to prevent or manage the drug interaction (the table is not all inclusive). The drug interactions described are based on studies conducted with either ODEFSEY, the components of ODEFSEY (FTC, RPV and TAF) as individual agents, or are predicted drug interactions that may occur with ODEFSEY <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>, Tables 9â12].</content> For list of contraindicated drugs, <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>].</content>
                        </paragraph>
                        <table width="85%" ID="Tb4">
                           <caption>Table 4	Significant<footnote>This table is not all inclusive.</footnote> Drug Interactions </caption>
                           <col width="30%" align="left" valign="top"/>
                           <col width="35%" align="left" valign="top"/>
                           <col width="35%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" valign="middle">Concomitant Drug Class: Drug Name</th>
                                 <th styleCode="Rrule" align="center" valign="middle">Effect  on Concentration<footnote>Increase=â; Decrease=â; No Effect=â</footnote>
                                 </th>
                                 <th styleCode="Rrule" align="center" valign="middle">Clinical  Comment</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antacids:</content>
                                    <br/> Â Â antacids<br/>Â Â (e.g., aluminum, magnesium hydroxide, or calcium carbonate)</td>
                                 <td styleCode="Rrule">â RPV<br/>(antacids taken at least 2 hours before or at least 4 hours after RPV)<br/>â RPV (concomitant intake)</td>
                                 <td styleCode="Rrule">Administer antacids at least 2 hours before or at least 4 hours after ODEFSEY.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Anticonvulsants:</content>
                                    <br/>Â Â carbamazepine <br/>Â Â oxcarbazepine <br/>Â Â phenobarbital <br/>Â Â phenytoin</td>
                                 <td styleCode="Rrule">â RPV</td>
                                 <td styleCode="Rrule">Coadministration is contraindicated due to potential for loss of virologic response and development of resistance.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antimycobacterials:</content>
                                    <br/>Â Â rifampin<br/>Â Â rifapentine</td>
                                 <td styleCode="Rrule">â RPV</td>
                                 <td styleCode="Rrule">Coadministration is contraindicated due to potential for loss of virologic response and development of resistance.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antimycobacterials:</content>
                                    <br/>Â Â rifabutin</td>
                                 <td styleCode="Rrule">â RPV<footnote ID="t3fc">The interaction was evaluated in a clinical study. All other drug interactions shown are predicted.</footnote>
                                    <br/>â TAF</td>
                                 <td styleCode="Rrule">Coadministration of ODEFSEY with rifabutin is not recommended.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Azole Antifungal Agents:<br/>
                                    </content>Â Â fluconazole<br/>Â Â itraconazole<br/>Â Â ketoconazole<br/>Â Â posaconazole <br/>Â Â voriconazole</td>
                                 <td styleCode="Rrule">â RPV<footnoteRef IDREF="t3fc"/>
                                    <sup>,</sup>
                                    <footnote ID="t3fd">This interaction study has been performed with a dose higher than the recommended dose for RPV. The dosing recommendation is applicable to the recommended dose of RPV 25 mg once daily.</footnote>
                                    <br/>âÂ­ TAF<br/>â ketoconazole<footnoteRef IDREF="t3fc"/>
                                    <sup>,</sup>
                                    <footnoteRef IDREF="t3fd"/>
                                 </td>
                                 <td styleCode="Rrule">No dosage adjustment is required when ODEFSEY is coadministered with azole antifungal agents. Clinically monitor for breakthrough fungal infections when azole antifungals are coadministered with ODEFSEY.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Glucocorticoid (systemic): </content>
                                    <br/>Â Â dexamethasone (more than a single dose)</td>
                                 <td styleCode="Rrule">â RPV</td>
                                 <td styleCode="Rrule">Coadministration is contraindicated due to potential for loss of virologic response and development of resistance.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">H<sub>2</sub>-Receptor Antagonists:</content>
                                    <br/>Â Â cimetidine   <br/>Â Â famotidine<br/>Â Â nizatidine<br/>Â Â ranitidine</td>
                                 <td styleCode="Rrule">â RPV<footnoteRef IDREF="t3fc"/>
                                    <sup>,</sup>
                                    <footnoteRef IDREF="t3fd"/>
                                    <br/>(famotidine taken 12 hours before RPV or 4 hours after RPV)<br/>â RPV<footnoteRef IDREF="t3fc"/>
                                    <sup>,</sup>
                                    <footnoteRef IDREF="t3fd"/>
                                    <br/>(famotidine taken 2 hours before RPV)</td>
                                 <td styleCode="Rrule">Administer H<sub>2</sub>-receptor antagonists at least 12 hours before or at least 4 hours after ODEFSEY.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Herbal Products:</content>
                                    <br/>Â Â St. John's wort <content styleCode="italics">(Hypericum perforatum)</content>
                                 </td>
                                 <td styleCode="Rrule">â RPV</td>
                                 <td styleCode="Rrule">Coadministration is contraindicated due to potential for loss of virologic response and development of resistance.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Macrolide or Ketolide Antibiotics:</content>
                                    <br/>Â Â clarithromycin <br/>Â Â erythromycin <br/>Â Â telithromycin</td>
                                 <td styleCode="Rrule">âÂ­ RPV<br/>â clarithromycin<br/>â erythromycin<br/>â telithromycin</td>
                                 <td styleCode="Rrule">Where possible, alternatives such as azithromycin should be considered.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Narcotic Analgesics:</content>
                                    <br/>Â Â methadone</td>
                                 <td styleCode="Rrule">â R(â) methadone<footnoteRef IDREF="t3fc"/>
                                    <br/>â S(+) methadone<footnoteRef IDREF="t3fc"/>
                                    <br/>â RPV<footnoteRef IDREF="t3fc"/>
                                    <br/>â methadone<footnoteRef IDREF="t3fc"/> (when used with tenofovir)</td>
                                 <td styleCode="Rrule">No dosage adjustments are required when initiating coadministration of methadone with ODEFSEY. However, clinical monitoring is recommended, as methadone maintenance therapy may need to be adjusted in some patients.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Proton Pump Inhibitors:</content>
                                    <br/>e.g., dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole</td>
                                 <td styleCode="Rrule">â RPV</td>
                                 <td styleCode="Rrule">Coadministration is contraindicated due to potential for loss of virologic response and development of resistance.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.8">
                     <id root="5c0d72ba-7c59-4ce2-91bc-2fe60bc64687"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.8	Drugs Without Clinically Significant Interactions with ODEFSEY</title>
                     <text>
                        <paragraph>Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="c5df4c56-95b6-4f5b-b6a2-0fd0fdd81184"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Pregnancy: Total rilpivirine exposures were generally lower during pregnancy compared to the postpartum period. (<linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>, <linkHtml href="#S12.3">12.3</linkHtml>). </item>
                           <item>Pediatrics: Not recommended for patients weighing less than 25 kg. (<linkHtml href="#S8.4">8.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="270d6750-2a95-4fb6-a085-9137c93fc67b"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250224"/>
                     <component>
                        <section>
                           <id root="51ad9e73-5d56-4799-940b-78a2a9a3ab75"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Exposure Registry</content>
                              </paragraph>
                              <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to ODEFSEY during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.</paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8b706e86-2a1f-41ad-872e-be95a1bc3c82"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Available data from the APR show no statistically significant difference in the overall risk of major birth defects for emtricitabine (FTC), rilpivirine (RPV) or tenofovir alafenamide (TAF) compared with the background rate for major birth defects of 2.7% in a US reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP) <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>. The rate of miscarriage is not reported in the APR. The estimated background rate of miscarriage in the clinically recognized pregnancies in the U.S. general population is 15â20%.</paragraph>
                              <paragraph>Based on the experience of  pregnant individuals with HIV-1 who completed a clinical trial through the postpartum period with an RPV-based regimen, no dose adjustments are required for pregnant patients who are already on a stable RPV-containing regimen prior to pregnancy and who are virologically suppressed (HIV-1 RNA less than 50 copies per mL). Lower exposures of RPV were observed during pregnancy compared to the postpartum period. Therefore, viral load should be monitored closely <content styleCode="italics">[see <linkHtml href="#data">Data</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                              <paragraph>In animal studies, no adverse developmental effects were observed when the components of ODEFSEY were administered separately during the period of organogenesis at exposures up to 60 and 108 times (mice and rabbits, respectively; FTC), 15 and 70 times (rats and rabbits, respectively; RPV) and equal to and 53 times (rats and rabbits, respectively; TAF) the exposure at the recommended daily dose of these components in ODEFSEY <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>. Likewise, no adverse developmental effects were seen when FTC was administered to mice and RPV was administered to rats through lactation at exposures up to approximately 60 and 63 times, respectively, the exposure at the recommended daily dose of these components in ODEFSEY. No adverse effects were observed in the offspring when TDF was administered through lactation at tenofovir exposures of approximately 14 times the exposure at the recommended daily dosage of ODEFSEY.</paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="86ff1deb-55b0-4078-9f84-73dd773e0168"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                           <component>
                              <section>
                                 <id root="eab5380a-59b3-489c-b9c9-3751d84c3900"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>Prospective reports from the APR of overall major birth defects in pregnancies exposed to drug components of ODEFSEY are compared with a U.S. background major birth defect rate. Methodological limitations of the APR include the use of MACDP as the external comparator group. The MACDP population is not disease-specific, evaluates women and infants from a limited geographic area, and does not include outcomes for births that occurred at less than 20 weeks gestation.</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                                 <component>
                                    <section>
                                       <id root="97b3a2b6-d177-4d6f-bee4-f2ef5e6ab404"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Emtricitabine (FTC):</content>
                                          </paragraph>
                                          <paragraph>Based on prospective reports to the APR of over 5,400 exposures to FTC-containing regimens during pregnancy resulting in live births (including over 3,900 exposed in the first trimester and over 1,500 exposed in the second/third trimester), the prevalence of birth defects in live births was 2.6% (95% CI: 2.2% to 3.2%) and 2.7% (95% CI: 1.9% to 3.7%) following first and second/third trimester exposure, respectively, to FTC-containing regimens.</paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="17b48ffb-476a-4562-98f1-320c0b01f94c"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Rilpivirine (RPV):</content>
                                          </paragraph>
                                          <paragraph>RPV in combination with a background regimen was evaluated in a clinical trial of 19 pregnant participants with HIV-1 during the second and third trimesters and postpartum. Each of the subjects were on an RPV-based regimen at the time of enrollment. Twelve participants completed the trial through the postpartum period (6â12 weeks after delivery) and pregnancy outcomes are missing for six participants. The exposure (C<sub>0h</sub> and AUC) of total RPV was approximately 30 to 40% lower during pregnancy compared with postpartum (6 to 12 weeks). The protein binding of RPV was similar (&gt;99%) during second trimester, third trimester, and postpartum period <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. One participant discontinued the trial following fetal death at 25 weeks gestation due to suspected premature rupture of membranes. Among the 12 participants who were virologically suppressed at baseline (less than 50 copies/mL), virologic response was preserved in 10 participants (83.3%) through the third trimester visit and in 9 participants (75%) through the 6â12 week postpartum visit. Virologic outcomes during the third trimester visit were missing for two participants who were withdrawn (one participant was nonadherent to the study drug and one participant withdrew consent). Among the 10 infants with HIV test results available, born to 10  pregnant participants with HIV-1, all had test results that were negative for HIV-1 at the time of delivery and up to 16 weeks postpartum. All 10 infants received antiretroviral prophylactic treatment with zidovudine. RPV was well tolerated during pregnancy and postpartum. There were no new safety findings compared with the known safety profile of RPV in adults with HIV-1.</paragraph>
                                          <paragraph>Based on prospective reports to the APR of over 750 exposures to RPV-containing regimens during pregnancy resulting in live births (including over 550 exposed in the first trimester and over 200 exposed in the second/third trimester), the prevalence of birth defects in live births was 1.4% (95% CI: 0.6% to 2.8%) and 1.5% (95% CI: 0.3% to 4.3%) following first and second/third trimester exposure, respectively, to RPV-containing regimens.</paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="5b1c3eb6-4c9d-4c2f-be2d-159491cd9ab1"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Tenofovir Alafenamide (TAF):</content>
                                          </paragraph>
                                          <paragraph>Based on prospective reports to the APR of over 660 exposures to TAF-containing regimens during pregnancy resulting in live births (including over 520 exposed in the first trimester and over 130 exposed in the second/third trimester), the prevalence of birth defects in live births was 4.2% (95% CI: 2.6% to 6.3%) and 3.0% (95% CI: 0.8% to 7.5%) following first and second/third trimester exposure, respectively, to TAF-containing regimens.</paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3c63d3a6-b275-48d6-b13c-6ca1199e03f5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                                 <component>
                                    <section>
                                       <id root="a103e5ff-f8d8-47d3-bb27-eae67811dc4e"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Emtricitabine:</content> FTC was administered orally to pregnant mice (250, 500, or 1000 mg/kg/day) and rabbits (100, 300, or 1000 mg/kg/day) through organogenesis (on gestation days 6 through 15, and 7 through 19, respectively). No significant toxicological effects were observed in embryo-fetal toxicity studies performed with FTC in mice at exposures (AUC) approximately 60 times higher and in rabbits at approximately 108 times higher than human exposures at the recommended daily dose. In a pre/postnatal development study with FTC, mice were administered doses up to 1000 mg/kg/day; no significant adverse effects directly related to drug were observed in the offspring exposed daily from before birth (<content styleCode="italics">in utero</content>) through sexual maturity at daily exposures (AUC) of approximately 60-fold higher than human exposures at the recommended daily dose.</paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="503e5c38-187c-4961-b051-8e6a606722c5"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Rilpivirine:</content> RPV was administered orally to pregnant rats (40, 120, or 400 mg/kg/day) and rabbits (5, 10, or 20 mg/kg/day) through organogenesis (on gestation days 6 through 17, and 6 through 19, respectively). No significant toxicological effects were observed in embryo-fetal toxicity studies performed with RPV in rats and rabbits at exposures 15 (rats) and 70 (rabbits) times higher than the exposure in humans at the recommended dose of 25 mg once daily. In a pre/postnatal development study with RPV, where rats were administered up to 400 mg/kg/day through lactation, no significant adverse effects directly related to drug were noted in the offspring.</paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="d03b9474-bde8-4f68-bb42-a98eabc95b55"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Tenofovir Alafenamide:</content> TAF was administered orally to pregnant rats (25, 100, or 250 mg/kg/day) and rabbits (10, 30, or 100 mg/kg/day) through organogenesis (on gestation days 6 through 17, and 7 through 20, respectively). No adverse embryo-fetal effects were observed in rats and rabbits at TAF exposures similar to (rats) and approximately 53 (rabbits) times higher than the exposure in humans at the recommended daily dose of ODEFSEY. TAF is rapidly converted to tenofovir; the observed tenofovir exposure in rats and rabbits were 59 (rats) and 93 (rabbits) times higher than human tenofovir exposures at the recommended daily doses. Since TAF is rapidly converted to tenofovir and a lower tenofovir exposure in rats and mice was observed after TAF administration compared to tenofovir disoproxil fumarate (TDF, another prodrug for tenofovir) administration, a pre/postnatal development study in rats was conducted only with TDF. Doses up to 600 mg/kg/day were administered through lactation, no adverse effects were observed in the offspring on gestation day 7 [and lactation day 20] at tenofovir exposures of approximately 14 [21] times higher than the exposures in humans at the recommended daily dose of ODEFSEY.</paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="08e276c4-b9ce-423f-bce1-fab5ade66397"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250224"/>
                     <component>
                        <section>
                           <id root="4dd4de81-06de-46aa-8380-815774f74267"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Data from the published literature report the presence of FTC, TAF, and TFV (tenofovir) in human milk; it is unknown if RPV is present in human milk. RPV is present in rat milk <content styleCode="italics">(see <linkHtml href="#data2">Data</linkHtml>).</content> Data from the published literature have not reported adverse effects of FTC or TAF on a breastfed child; it is not known if RPV has effects on the breastfed child. It is not known if the components of ODEFSEY affect milk production.</paragraph>
                              <paragraph>Potential risks of breastfeeding include: (1) HIV-1 transmission to infants without HIV-1, (2) developing viral resistance in infants with HIV-1, and (3) adverse reactions in a breastfed infant similar to those seen in adults.</paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data2">
                           <id root="5de83904-f417-4626-b8eb-6c0e10b12780"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                           <component>
                              <section>
                                 <id root="769b2a3d-4ab2-4a84-a35f-aff5419bd53b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Rilpivirine:</content> In animals, no studies have been conducted to assess the excretion of RPV directly; however, RPV was measured in rat pups which were exposed through the milk of treated dams (dosed up to 400 mg/kg/day).</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="12e15638-dc0c-4e8e-a016-2aaa69919c3e"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The efficacy and safety of ODEFSEY as a complete regimen for the treatment of HIV-1  was established in pediatric patients 6 years of age and older with body weight greater than or equal to 25 kg <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>].</content> No pediatric clinical trials were conducted with ODEFSEY<content styleCode="italics">.</content> Use of ODEFSEY in this age group is supported by adequate and well-controlled studies of RPV+FTC+TDF in adults with HIV-1 infection, adequate and well-controlled studies of FTC+TAF with EVG+COBI in adults with HIV-1, and by the following pediatric studies conducted using the components of ODEFSEY <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>48-week open-label trials of antiretroviral treatment-naÃ¯ve pediatric participants with HIV-1 aged 12 to less than 18 years and weighing at least 32 kg (N=36) and aged 6 to less than 12 years weighing at least 17 kg (N=18) treated with RPV and other antiretrovirals. The safety and efficacy of RPV administered with other antiretrovirals were similar to that in antiretroviral treatment-naÃ¯ve adults with HIV-1 on this regimen <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content>
                           </item>
                           <item>48-week open-label trial of 26 virologically-suppressed pediatric participants with HIV-1 aged less than 12 years old and weighing at least 16 kg (N=26) treated with RPV and other antiretrovirals. The safety and efficacy of RPV administered with other antiretrovirals were similar to that in virologically-suppressed adults with HIV-1 on this regimen <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>
                           </item>
                           <item>48-week open-label trials of antiretroviral treatment-naÃ¯ve pediatric participants with HIV-1 aged 12 to less than 18 years and weighing at least 35 kg (N=50) and virologically-suppressed pediatric participants between the ages of 6 to less than 12 years weighing at least 25 kg (N=52) treated with FTC+TAF with EVG+COBI. The safety and efficacy of FTC+TAF with EVG+COBI were similar to that in adults with HIV-1 on this regimen, with the exception of a decrease from baseline in CD4+ cell counts in participants 6 to less than 12 years of age weighing at least 25 kg <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content>
                           </item>
                        </list>
                        <paragraph>Because it is a fixed-dose combination tablet, the dose of ODEFSEY cannot be adjusted for patients of lower age and weight. The safety and efficacy of ODEFSEY have not been established in pediatric patients weighing less than 25 kg <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="678e71fc-fb87-4d26-a7ac-0f85365c8a6c"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In clinical trials, 80 of the 97 participants enrolled aged 65 years and over received FTC+TAF with EVG+COBI. No differences in safety or efficacy have been observed between elderly participants and those between 12 and less than 65 years of age. Clinical trials of RPV did not include sufficient numbers of participants aged 65 years and over to determine whether they respond differently from younger participants <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="5d1f5cf7-17be-4e5d-b587-60212fc5914e"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment of ODEFSEY is recommended in patients with estimated creatinine clearance greater than or equal to 30 mL per minute. ODEFSEY should be used with caution in adults patients with ESRD (estimated creatinine clearance below 15mL per minute) who are receiving chronic hemodialysis and increased monitoring is recommended for RPV-related adverse effects in patients with ESRD, as RPV concentrations may be increased due to alteration of drug absorption, distribution, and metabolism secondary to renal dysfunction. On days of hemodialysis, administer the daily dose of ODEFSEY after completion of hemodialysis treatment <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>ODEFSEY is not recommended in patients with severe renal impairment (estimated creatinine clearance of 15 to below 30 mL per minute), or in patients with ESRD who are not receiving chronic hemodialysis, as the safety of ODEFSEY has not been established in these populations <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="8aadef4a-884a-47da-8841-dedb18e4cf56"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment of ODEFSEY is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. ODEFSEY has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="5a73b58c-266d-4a91-b07b-7c13565e4858"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Limited data are available on overdose of the components of ODEFSEY in patients. If overdose occurs, monitor the patient for evidence of toxicity. Treatment of overdose with ODEFSEY consists of general supportive measures including monitoring of vital signs and ECG (QT interval) as well as observation of the clinical status of the patient.</paragraph>
               </text>
               <effectiveTime value="20250224"/>
               <component>
                  <section>
                     <id root="c03bf3ec-a825-4b54-93b3-36db4cc1096f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Emtricitabine (FTC):</content> Hemodialysis treatment removes approximately 30% of the FTC dose over a 3-hour dialysis period starting within 1.5 hours of FTC dosing (blood flow rate of 400 mL per minute and a dialysate flow rate of 600 mL per minute). It is not known whether FTC can be removed by peritoneal dialysis.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0c28fdd1-fc50-4573-8ca1-ec6d10c7ada7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Rilpivirine (RPV):</content> Human experience of overdose with RPV is limited. There is no specific antidote for overdose with RPV. Since RPV is highly bound to plasma protein, dialysis is unlikely to result in significant removal of RPV.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="543607b2-55b2-4264-b790-5be0063e04f0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Tenofovir Alafenamide (TAF):</content> Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="40704c1d-8c33-423a-a294-78f7a63eda94"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>ODEFSEY (emtricitabine, rilpivirine, and tenofovir alafenamide) is a fixed-dose combination tablet containing emtricitabine (FTC), rilpivirine (RPV), and tenofovir alafenamide (TAF) for oral administration.</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>FTC, a synthetic nucleoside analog of cytidine, is an HIV-1 nucleoside analog reverse transcriptase inhibitor (HIV-1 NRTI).</item>
                     <item>RPV is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI).</item>
                     <item>TAF, an HIV-1 NRTI, is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5â²-monophosphate.</item>
                  </list>
                  <paragraph>Each tablet contains 200 mg of FTC, 25 mg of RPV (equivalent to 27.5 of rilpivirine hydrochloride) and 25 mg of TAF (equivalent to 28 mg of tenofovir alafenamide fumarate) and the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polysorbate 20, and povidone. The tablets are film-coated with a coating material containing iron oxide black, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.</paragraph>
               </text>
               <effectiveTime value="20250224"/>
               <component>
                  <section>
                     <id root="3521ca24-06c1-4717-bbd0-1ff83cab24c4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Emtricitabine:</content> The chemical name of FTC is 4-amino-5-fluoro-1-(2<content styleCode="italics">R</content>-hydroxymethyl-1,3-oxathiolan-5<content styleCode="italics">S</content>-yl)-(1<content styleCode="italics">H</content>)-pyrimidin-2-one. FTC is the (-)enantiomer of a thio analog of cytidine, which differs from other cytidine analogs in that it has a fluorine in the 5 position.</paragraph>
                        <paragraph>FTC has a molecular formula of C<sub>8</sub>H<sub>10</sub>FN<sub>3</sub>O<sub>3</sub>S and a molecular weight of 247.24 and has the following structural formula:</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM1"/>
                        </paragraph>
                        <paragraph>FTC is a white to off-white powder with a solubility of approximately 112 mg per mL in water at 25 Â°C.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="62774ba9-d2ba-4272-b64f-2af4926ff359"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Rilpivirine:</content> The chemical name of rilpivirine hydrochloride drug substance is 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile monohydrochloride. Its molecular formula is C<sub>22</sub>H<sub>18</sub>N<sub>6</sub> â HCl and its molecular weight is 402.88. Rilpivirine hydrochloride has the following structural formula:</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM2"/>
                        </paragraph>
                        <paragraph>Rilpivirine hydrochloride is a white to almost white powder. Rilpivirine hydrochloride is practically insoluble in water over a wide pH range.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c9b8df5b-9658-4e91-813c-8309f62a857d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Tenofovir Alafenamide:</content> The chemical name of tenofovir alafenamide fumarate drug substance is L-alanine, <content styleCode="italics">N</content>-[(<content styleCode="italics">S</content>)-[[(1<content styleCode="italics">R</content>)-2-(6-amino-9<content styleCode="italics">H</content>-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester, (2<content styleCode="italics">E</content>)-2-butenedioate (2:1).</paragraph>
                        <paragraph>Tenofovir alafenamide fumarate has an empirical formula of C<sub>21</sub>H<sub>29</sub>O<sub>5</sub>N<sub>6</sub>PâÂ½(C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>) and a formula weight of 534.50 and has the following structural formula:</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM3"/>
                        </paragraph>
                        <paragraph>Tenofovir alafenamide fumarate is a white to off-white or tan powder with a solubility of 4.7 mg per mL in water at 20 Â°C.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="odefsey-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="odefsey-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="odefsey-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="01721921-7467-4c09-a70c-bdda289c644f"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250224"/>
               <component>
                  <section ID="S12.1">
                     <id root="7139a5bc-1c24-4912-b205-59f76fca0f26"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1	Mechanism of Action</title>
                     <text>
                        <paragraph>ODEFSEY is a fixed dose combination of antiretroviral drugs emtricitabine, rilpivirine, and tenofovir alafenamide <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="4d7f4611-2fdd-4e15-ab14-c37e296778a7"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20250224"/>
                     <component>
                        <section>
                           <id root="d15c1735-9c95-4bd4-9cf0-4f57855a36b7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>When higher than recommended RPV doses of 75 mg (3 times the recommended dosage in ODEFSEY) once daily and 300 mg (12 times the recommended dosage in ODEFSEY) once daily were studied in healthy adults, the maximum mean time-matched (95% upper confidence bound) differences in QTcF interval from placebo after baseline correction were 10.7 (15.3) and 23.3 (28.4) milliseconds, respectively. Steady-state administration of RPV 75 mg once daily and 300 mg once daily resulted in a mean steady-state C<sub>max</sub> approximately 2.6 times and 6.7 times, respectively, higher than the mean C<sub>max</sub> observed with the recommended 25 mg once daily dose of RPV <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>.</paragraph>
                              <paragraph>The effect of RPV at the recommended dose of 25 mg once daily on the QTcF interval was evaluated in a randomized, placebo-, and active- (moxifloxacin 400 mg once daily) controlled crossover study in 60 healthy adults, with 13 measurements over 24 hours at steady state. The maximum mean time-matched (95% upper confidence bound) differences in QTcF interval from placebo after baseline correction was 2 (5) milliseconds (i.e., below the threshold of clinical concern).</paragraph>
                              <paragraph>In a thorough QT/QTc study in 48 healthy participants, TAF at the recommended dose and at a dose approximately 5 times the recommended dose, did not affect the QT/QTc interval and did not prolong the PR interval.</paragraph>
                              <paragraph>The effect of FTC on the QT interval is not known.</paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="65532748-5ec9-43ec-80bc-72b8309c9550"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20250224"/>
                     <component>
                        <section>
                           <id root="f9c05659-1fc2-482f-8576-6eff48a00ce2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption, Distribution, Metabolism, and Excretion</content>
                              </paragraph>
                              <paragraph>The pharmacokinetic properties of the components of ODEFSEY are provided in Table 5. The multiple dose pharmacokinetic parameters of FTC, RPV and TAF and its metabolite tenofovir are provided in Table 6.</paragraph>
                              <table width="75%">
                                 <caption>Table 5	Pharmacokinetic Properties of the Components of ODEFSEY </caption>
                                 <col width="40%" align="left" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Rilpivirine</th>
                                       <th styleCode="Rrule">Emtricitabine</th>
                                       <th styleCode="Rrule">Tenofovir Alafenamide</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">PBMCs = peripheral blood mononuclear cells; CES1 = carboxylesterase 1.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="4">
                                          <content styleCode="bold">Absorption</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">T<sub>max</sub> (h)</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Effect of moderate fat meal (relative to fasting)<footnote ID="t4fa">Values refer to geometric mean ratio [fed/ fasted] in PK parameters and (90% confidence interval). High-calorie/high-fat meal = ~800 kcal, 50% fat. Moderate-fat meal = ~600 kcal, 27% fat.</footnote>
                                       </td>
                                       <td styleCode="Rrule">AUC Ratio = 1.13 (1.03, 1.23)</td>
                                       <td styleCode="Rrule">AUC Ratio = 0.91 (0.89, 0.93)</td>
                                       <td styleCode="Rrule">AUC Ratio = 1.45<br/>(1.33, 1.58)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Effect of high fat meal (relative to fasting)<footnoteRef IDREF="t4fa"/>
                                       </td>
                                       <td styleCode="Rrule">AUC Ratio = 1.72 (1.49, 1.99)</td>
                                       <td styleCode="Rrule">AUC Ratio = 0.88 (0.85, 0.90)</td>
                                       <td styleCode="Rrule">AUC Ratio = 1.53<br/>(1.39, 1.69)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="4">
                                          <content styleCode="bold">Distribution</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">% Bound to human plasma proteins</td>
                                       <td styleCode="Rrule">~99</td>
                                       <td styleCode="Rrule">&lt;4</td>
                                       <td styleCode="Rrule">~80</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Source of protein binding data</td>
                                       <td styleCode="Rrule">In vitro</td>
                                       <td styleCode="Rrule">In vitro</td>
                                       <td styleCode="Rrule">Ex vivo</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Blood-to-plasma ratio</td>
                                       <td styleCode="Rrule">0.7</td>
                                       <td styleCode="Rrule">0.6</td>
                                       <td styleCode="Rrule">1.0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="4">
                                          <content styleCode="bold">Metabolism</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Metabolism</td>
                                       <td styleCode="Rrule">CYP3A</td>
                                       <td styleCode="Rrule">Not significantly metabolized</td>
                                       <td styleCode="Rrule">Cathepsin A<footnote>In vivo, TAF is hydrolyzed within cells to form tenofovir (major metabolite), which is phosphorylated to the active metabolite, tenofovir diphosphate. In vitro studies have shown that TAF is metabolized to tenofovir by cathepsin A in PBMCs and macrophages; and by CES1 in hepatocytes. Upon coadministration with the moderate CYP3A inducer probe efavirenz, TAF exposure was unaffected.</footnote> (PBMCs)<br/>CES1 (hepatocytes)<br/>CYP3A (minimal)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="4">
                                          <content styleCode="bold">Elimination</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Major route of elimination</td>
                                       <td styleCode="Rrule">Metabolism</td>
                                       <td styleCode="Rrule">Glomerular filtration and active tubular secretion</td>
                                       <td styleCode="Rrule">Metabolism (&gt;80% of oral dose)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">t<sub>1/2 </sub>(h)<footnote ID="t4fc">t<sub>1/2</sub> values refer to median terminal plasma half-life. Note that the pharmacologically active metabolite, tenofovir diphosphate, has a half-life of 150â180 hours within PBMCs.</footnote>
                                       </td>
                                       <td styleCode="Rrule">50</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">0.51</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">% Of dose excreted in urine<footnote ID="t4fd">Dosing in mass balance studies: FTC (single dose administration of [<sup>14</sup>C] emtricitabine after multiple dosing of emtricitabine for ten days); TAF (single dose administration of [<sup>14</sup>C] tenofovir alafenamide).</footnote>
                                       </td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">70</td>
                                       <td styleCode="Rrule">&lt;1</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">% Of dose excreted in feces<footnoteRef IDREF="t4fd"/>
                                       </td>
                                       <td styleCode="Rrule">85</td>
                                       <td styleCode="Rrule">13.7</td>
                                       <td styleCode="Rrule">31.7</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="75%" ID="Tb6">
                                 <caption>Table 6	Multiple Dose Pharmacokinetic Parameters of Emtricitabine, Rilpivirine, Tenofovir Alafenamide and its Metabolite Tenofovir Following Oral Administration with a Meal in Adults with HIV-1</caption>
                                 <col width="20%" align="left" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" align="center">Parameter<br/>Mean (CV%)</th>
                                       <th styleCode="Rrule">Emtricitabine<footnote>From Intensive PK analysis in a phase 2 trial in adults with HIV-1 treated with FTC+TAF with EVG+COBI (n=19).</footnote>
                                       </th>
                                       <th styleCode="Rrule">Rilpivirine<footnote>From Population PK analysis in a trial of treatment-naÃ¯ve adults with HIV-1 treated with RPV (n=679).</footnote>
                                       </th>
                                       <th styleCode="Rrule">Tenofovir Alafenamide<footnote>From Population PK analysis in two trials of treatment-naÃ¯ve adults with HIV-1 treated within EVG+COBI+FTC+TAF (n=539).</footnote>
                                       </th>
                                       <th styleCode="Rrule">Tenofovir<footnote>From Population PK analysis in two trials of treatment-naÃ¯ve adults with HIV-1 treated with EVG+COBI+FTC+TAF (n=841).</footnote>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">CV = Coefficient of Variation; NA = Not Applicable</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">C<sub>max</sub>
                                          <br/>(microgram per mL)</td>
                                       <td styleCode="Rrule">2.1 (20.2)</td>
                                       <td styleCode="Rrule">NA</td>
                                       <td styleCode="Rrule">0.16 (51.1)</td>
                                       <td styleCode="Rrule">0.02 (26.1)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">AUC<sub>tau</sub>
                                          <br/>(microgramâhour per mL)</td>
                                       <td styleCode="Rrule">11.7 (16.6)</td>
                                       <td styleCode="Rrule">2.2 (38.1)</td>
                                       <td styleCode="Rrule">0.21 (71.8)</td>
                                       <td styleCode="Rrule">0.29 (27.4)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">C<sub>trough</sub>
                                          <br/>(microgram per mL)</td>
                                       <td styleCode="Rrule">0.10 (46.7)</td>
                                       <td styleCode="Rrule">0.08 (44.3)</td>
                                       <td styleCode="Rrule">NA</td>
                                       <td styleCode="Rrule">0.01 (28.5)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="40347a20-47c4-4e11-ab92-9b6d69ec36c9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                           <component>
                              <section>
                                 <id root="42b358f8-1f37-485b-8668-62ac226ed803"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Geriatric Patients</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of FTC and TAF have not been fully evaluated in the elderly (65 years of age and older). Population pharmacokinetics analysis of participants with HIV-1 in Phase 2 and Phase 3 trials of FTC+TAF with EVG+COBI showed that age did not have a clinically relevant effect on exposures of TAF up to 75 years of age.</paragraph>
                                    <paragraph>The pharmacokinetics of RPV have not been fully evaluated in the elderly (65 years of age and older) <content styleCode="italics">[see <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="d2ac6745-6e90-499e-8608-adac9b18ff9b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric Patients</content>
                                    </paragraph>
                                    <paragraph>Exposures of TAF in 24 pediatric participants with HIV-1 aged 12 to less than 18 years who received FTC+TAF with EVG+COBI were decreased (23% for TAF AUC) compared to exposures achieved in treatment-naÃ¯ve adults following administration of FTC+TAF with EVG+COBI. These exposure differences are not thought to be clinically significant based on exposure-response relationships. FTC exposures were similar in adolescents compared to treatment-naÃ¯ve adults.</paragraph>
                                    <paragraph>Exposures of FTC, TAF and TFV in 23 pediatric participants with HIV-1 aged 6 to less than 12 years who received FTC+TAF with EVG+COBI were higher (50 to 80% for AUC) than exposures achieved in adults following the administration of FTC+TAF with EVG+COBI, however, the increase was not considered clinically significant as the safety profiles were similar in adult and pediatric participants.</paragraph>
                                    <paragraph>The PK of RPV in pediatric participants with HIV aged 6 to less than 18 years who received RPV 25 mg once daily were comparable to or slightly higher than those obtained in adults with HIV-1 <content styleCode="italics">[see <linkHtml href="#S8.4">Use In Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="88407153-d180-4d58-8867-ab5138ffae25"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Race and Gender</content>
                                    </paragraph>
                                    <paragraph>No clinically significant changes in the pharmacokinetics of the components of ODEFSEY have been observed based on race or gender.</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="9161b2ca-8a8f-4dc3-8edd-cd6d54407023"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                                 <component>
                                    <section>
                                       <id root="774d142e-af78-45f3-88f6-49b396bc8ab2"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Rilpivirine:</content> Population pharmacokinetic analysis indicated that RPV exposure was similar in participants with HIV-1 and eGFR 60 to 89 mL per minute by Cockcroft-Gault method, relative to participants with HIV-1 and normal renal function. There is limited or no information regarding the pharmacokinetics of RPV in patients with moderate or severe renal impairment or in patients with end-stage renal disease <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>]</content>.</paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="2930e027-b632-46ff-9837-fe0d37c6b8b5"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Emtricitabine and Tenofovir Alafenamide:</content> The pharmacokinetics of FTC+TAF with EVG+COBI in participants with HIV-1 and renal impairment (eGFR 30 to 69 mL per minute by Cockcroft-Gault method), and in participants with HIV-1 and ESRD (estimated creatinine clearance of less than 15 mL per minute by Cockcroft-Gault method) receiving chronic hemodialysis were evaluated in subsets of virologically-suppressed participants in open-label trials. The pharmacokinetics of TAF were similar among healthy participants, participants with HIV-1 and mild or moderate renal impairment, and participants with HIV-1 and ESRD receiving chronic hemodialysis; increases in FTC and TFV exposures in participants with HIV-1 and renal impairment were not considered clinically relevant (Table 7).</paragraph>
                                          <table width="75%" ID="Tb7">
                                             <caption>Table 7	Pharmacokinetics of FTC and a Metabolite of TAF (Tenofovir) in Adults with HIV-1 and Renal Impairment as Compared to Participants with Normal Renal Function</caption>
                                             <col width="28%" align="left" valign="middle"/>
                                             <col width="18%" align="center" valign="middle"/>
                                             <col width="18%" align="center" valign="middle"/>
                                             <col width="18%" align="center" valign="middle"/>
                                             <col width="18%" align="center" valign="middle"/>
                                             <thead>
                                                <tr styleCode="Botrule">
                                                   <th styleCode="Lrule Rrule"/>
                                                   <th styleCode="Rrule" colspan="4">AUC<sub>tau </sub>(microgram-hour per mL)<br/>Mean (CV%)</th>
                                                </tr>
                                                <tr>
                                                   <th styleCode="Lrule Rrule">Estimated Creatinine Clearance<footnote>By Cockcroft-Gault method.</footnote>
                                                   </th>
                                                   <th styleCode="Rrule">â¥90 mL per minute (N=18)<footnote>From a phase 2 trial in adults with HIV-1 and normal renal function treated with FTC+TAF with EVG+COBI.</footnote>
                                                   </th>
                                                   <th styleCode="Rrule">60â89 mL per minute (N=11)<footnote>These participants had an eGFR ranging from 60 to 69 mL per minute.</footnote>
                                                   </th>
                                                   <th styleCode="Rrule">30â59 mL per minute (N=18)<footnote>From a phase 3 trial in adults with HIV-1 and renal impairment treated with FTC+TAF with EVG+COBI.</footnote>
                                                   </th>
                                                   <th styleCode="Rrule">&lt;15 mL per minute (N=12)<footnote>From a phase 3 trial in adults with HIV-1 and ESRD receiving chronic hemodialysis treated with FTC+TAF with EVG+COBI; PK assessed prior to hemodialysis following 3 consecutive daily doses of FTC+TAF with EVG+COBI.</footnote>
                                                   </th>
                                                </tr>
                                             </thead>
                                             <tbody>
                                                <tr styleCode="Botrule">
                                                   <td styleCode="Lrule Rrule">Emtricitabine</td>
                                                   <td styleCode="Rrule">11.4 (11.9)</td>
                                                   <td styleCode="Rrule">17.6 (18.2)</td>
                                                   <td styleCode="Rrule">23.0 (23.6)</td>
                                                   <td styleCode="Rrule">62.9 (48.0)<footnote>N=11.</footnote>
                                                   </td>
                                                </tr>
                                                <tr>
                                                   <td styleCode="Lrule Rrule">Tenofovir</td>
                                                   <td styleCode="Rrule">0.32 (14.9)</td>
                                                   <td styleCode="Rrule">0.46 (31.5)</td>
                                                   <td styleCode="Rrule">0.61 (28.4)</td>
                                                   <td styleCode="Rrule">8.72 (39.4)<footnote>N=10.</footnote>
                                                   </td>
                                                </tr>
                                             </tbody>
                                          </table>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="5f88813c-6346-4ae0-8ab8-20f11d47c483"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                                 <component>
                                    <section>
                                       <id root="10e7d096-16ef-4b09-a1a7-3559d051f500"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Emtricitabine:</content> The pharmacokinetics of FTC have not been studied in participants with hepatic impairment; however, FTC is not significantly metabolized by liver enzymes, so the impact of hepatic impairment should be limited.</paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="8b6b6145-4cc0-4967-b506-f73163defa83"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Rilpivirine:</content> In a study comparing 8 participants with mild hepatic impairment (Child-Pugh score A) to 8 matched controls and 8 participants with moderate hepatic impairment (Child-Pugh score B) to 8 matched controls, the multiple-dose exposure of RPV was 47% higher in participants with mild hepatic impairment and 5% higher in participants with moderate hepatic impairment <content styleCode="italics">[see <linkHtml href="#S8.7">Use in Specific Populations (8.7)</linkHtml>]</content>.</paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="e9f1f8a6-dd5f-4932-a094-9b69b638c4c3"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Tenofovir Alafenamide:</content> Clinically relevant changes in the pharmacokinetics of  tenofovir alafenamide or its metabolite tenofovir were not observed in participants with mild, moderate (Child-Pugh A and B), or severe hepatic impairment (Child-Pugh C) <content styleCode="italics">[see <linkHtml href="#S8.7">Use in Specific Populations (8.7)</linkHtml>]</content>.</paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="141df023-3658-430a-b993-4839f24880cc"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hepatitis B and/or Hepatitis C Virus Coinfection</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of FTC and TAF have not been fully evaluated in participants with hepatitis B and/or C virus. Population pharmacokinetic analysis indicated that hepatitis B and/or C virus coinfection had no clinically relevant effect on the exposure of RPV.</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="1d64ed67-34d1-452d-94a5-5f32a74e6ee4"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pregnancy and Postpartum</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                                 <component>
                                    <section>
                                       <id root="2b522b3c-aa5d-4414-a277-aa3b6e4839d8"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Rilpivirine:</content> The exposure (C<sub>0h</sub> and AUC<sub>24h</sub>) to total RPV after intake of RPV 25 mg once daily as part of an antiretroviral regimen was 30 to 40% lower during pregnancy (similar for the second and third trimester), compared with postpartum (see <linkHtml href="#Tb8">Table 8</linkHtml>). However, the exposure during pregnancy was not significantly different from exposures obtained in Phase 3 trials of RPV-containing regimens. Based on the exposure-response relationship for RPV, this decrease is not considered clinically relevant in patients who are virologically-suppressed. The protein binding of RPV was similar (&gt;99%) during the second trimester, third trimester, and postpartum.</paragraph>
                                          <table width="80%" ID="Tb8">
                                             <caption>Table 8	Pharmacokinetic Results of Total Rilpivirine After Administration of Rilpivirine 25 mg Once Daily as Part of an Antiretroviral Regimen, During the 2nd Trimester of Pregnancy, the 3rd Trimester of Pregnancy and Postpartum</caption>
                                             <col width="38%" align="left" valign="top"/>
                                             <col width="20%" align="center" valign="top"/>
                                             <col width="20%" align="center" valign="top"/>
                                             <col width="22%" align="center" valign="top"/>
                                             <thead>
                                                <tr>
                                                   <th styleCode="Lrule Rrule">Pharmacokinetics of total rilpivirine<br/>(mean Â± SD, t<sub>max</sub>: median [range])</th>
                                                   <th styleCode="Rrule">Postpartum<br/>(6â12 Weeks)<br/>(n=11)</th>
                                                   <th styleCode="Rrule">2<sup>nd</sup> Trimester of pregnancy<br/>(n=15)</th>
                                                   <th styleCode="Rrule">3<sup>rd</sup> Trimester of pregnancy<br/>(n=13)</th>
                                                </tr>
                                             </thead>
                                             <tbody>
                                                <tr styleCode="Botrule">
                                                   <td styleCode="Lrule Rrule">C<sub>0h</sub>, ng/mL</td>
                                                   <td styleCode="Rrule">111 Â± 69.2</td>
                                                   <td styleCode="Rrule">65.0 Â± 23.9</td>
                                                   <td styleCode="Rrule">63.5 Â± 26.2</td>
                                                </tr>
                                                <tr styleCode="Botrule">
                                                   <td styleCode="Lrule Rrule">C<sub>min</sub>, ng/mL</td>
                                                   <td styleCode="Rrule">84.0 Â± 58.8</td>
                                                   <td styleCode="Rrule">54.3 Â± 25.8</td>
                                                   <td styleCode="Rrule">52.9 Â± 24.4</td>
                                                </tr>
                                                <tr styleCode="Botrule">
                                                   <td styleCode="Lrule Rrule">C<sub>max</sub>, ng/mL</td>
                                                   <td styleCode="Rrule">167 Â± 101</td>
                                                   <td styleCode="Rrule">121 Â± 45.9</td>
                                                   <td styleCode="Rrule">123 Â± 47.5</td>
                                                </tr>
                                                <tr styleCode="Botrule">
                                                   <td styleCode="Lrule Rrule">t<sub>max</sub>, h</td>
                                                   <td styleCode="Rrule">4.00 (2.03â25.08)</td>
                                                   <td styleCode="Rrule">4.00 (1.00â9.00)</td>
                                                   <td styleCode="Rrule">4.00 (2.00â24.93)</td>
                                                </tr>
                                                <tr>
                                                   <td styleCode="Lrule Rrule">AUC<sub>24h</sub>, ng.h/mL</td>
                                                   <td styleCode="Rrule">2714 Â± 1535</td>
                                                   <td styleCode="Rrule">1792 Â± 711</td>
                                                   <td styleCode="Rrule">1762 Â± 662</td>
                                                </tr>
                                             </tbody>
                                          </table>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a476b241-0de5-4d72-aff0-c34fc47b7c8b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                           <component>
                              <section>
                                 <id root="d8844e35-d57a-46ce-b108-d494a450ec29"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Rilpivirine:</content> RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may thus affect the clearance of RPV.</paragraph>
                                    <paragraph>RPV at a dose of 25 mg once daily is not likely to have a clinically relevant effect on the exposure of medicinal products metabolized by CYP enzymes.</paragraph>
                                    <paragraph>TAF is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or UGT1A1. TAF is a weak inhibitor of CYP3A in vitro. TAF is not an inhibitor or inducer of CYP3A in vivo.</paragraph>
                                    <paragraph>The drug interaction studies described in Tables 9â12 were conducted with ODEFSEY (FTC/RPV/TAF) or the components of ODEFSEY (FTC, RPV, or TAF) administered individually.</paragraph>
                                    <paragraph>The effects of coadministered drugs on the exposures of RPV and TAF are shown in Tables 9 and 10, respectively. The effects of RPV and TAF on the exposure of coadministered drugs are shown in Tables 11 and 12, respectively. For information regarding clinical recommendations, <content styleCode="italics">see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>.</content>
                                    </paragraph>
                                    <table width="80%" ID="Tb9">
                                       <caption>Table 9	 Changes in Pharmacokinetic Parameters for RPV in the Presence of Coadministered Drugs in Healthy Participants</caption>
                                       <col width="20%" align="left" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <col width="12%" align="center" valign="middle"/>
                                       <col width="6%" align="center" valign="middle"/>
                                       <col width="14%" align="center" valign="middle"/>
                                       <col width="14%" align="center" valign="middle"/>
                                       <col width="14%" align="center" valign="middle"/>
                                       <thead>
                                          <tr>
                                             <th align="center" rowspan="2" styleCode="Lrule Rrule Botrule">Coadministered Drug</th>
                                             <th colspan="2" styleCode="Rrule Botrule">Dose/Schedule</th>
                                             <th styleCode="Rrule"/>
                                             <th colspan="3" styleCode="Rrule Botrule">Mean Ratio of RPV<br/>Pharmacokinetic Parameters With/Without Coadministered Drug (90% CI);<br/>No Effect = 1.00</th>
                                          </tr>
                                          <tr>
                                             <th align="center" styleCode="Lrule Rrule">Coadministered Drug (mg)</th>
                                             <th styleCode="Rrule">RPV (mg)</th>
                                             <th styleCode="Rrule" valign="top">N</th>
                                             <th styleCode="Rrule">C<sub>max</sub>
                                             </th>
                                             <th styleCode="Rrule">AUC</th>
                                             <th styleCode="Rrule">C<sub>min</sub>
                                             </th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td colspan="7" align="left" valign="top">CI=Confidence Interval; N=maximum number of participants with data; NA=Not Available; â=no change</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Acetaminophen</td>
                                             <td styleCode="Rrule">500 single dose</td>
                                             <td styleCode="Rrule">150 once daily<footnote ID="T8F1">25 mg, 75 mg, and 150 mg of RPV is 1, 3, and 6 times the recommended dose of RPV in ODEFSEY, respectively.</footnote>
                                             </td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">1.09<br/>(1.01, 1.18)</td>
                                             <td styleCode="Rrule">1.16<br/>(1.10, 1.22)</td>
                                             <td styleCode="Rrule">1.26<br/>(1.16, 1.38)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Atorvastatin</td>
                                             <td styleCode="Rrule">40 once daily</td>
                                             <td styleCode="Rrule">150 once daily<footnoteRef IDREF="T8F1"/>
                                             </td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">0.91<br/>(0.79, 1.06)</td>
                                             <td styleCode="Rrule">0.90<br/>(0.81, 0.99)</td>
                                             <td styleCode="Rrule">0.90<br/>(0.84, 0.96)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Chlorzoxazone</td>
                                             <td styleCode="Rrule">500 single dose taken 2 hours after RPV</td>
                                             <td styleCode="Rrule">150 once daily<footnoteRef IDREF="T8F1"/>
                                             </td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">1.17<br/>(1.08, 1.27)</td>
                                             <td styleCode="Rrule">1.25<br/>(1.16, 1.35)</td>
                                             <td styleCode="Rrule">1.18<br/>(1.09, 1.28)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Ethinylestradiol/Norethindrone</td>
                                             <td styleCode="Rrule">0.035 once daily /1 mg once daily</td>
                                             <td styleCode="Rrule">25 once daily<footnote ID="T8F2">Study conducted with RPV.</footnote>
                                             </td>
                                             <td styleCode="Rrule">15</td>
                                             <td styleCode="Rrule">â<footnote ID="T8F3">Comparison based on historic controls.</footnote>
                                             </td>
                                             <td styleCode="Rrule">â<footnoteRef IDREF="T8F3"/>
                                             </td>
                                             <td styleCode="Rrule">â<footnoteRef IDREF="T8F3"/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Famotidine</td>
                                             <td styleCode="Rrule">40 single dose taken 12 hours before RPV</td>
                                             <td styleCode="Rrule">150 single dose<footnoteRef IDREF="T8F1"/>
                                             </td>
                                             <td styleCode="Rrule">24</td>
                                             <td styleCode="Rrule">0.99<br/>(0.84, 1.16)</td>
                                             <td styleCode="Rrule">0.91<br/>(0.78, 1.07)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Famotidine</td>
                                             <td styleCode="Rrule">40 single dose taken 2 hours before RPV</td>
                                             <td styleCode="Rrule">150 single dose<footnoteRef IDREF="T8F1"/>
                                             </td>
                                             <td styleCode="Rrule">23</td>
                                             <td styleCode="Rrule">0.15<br/>(0.12, 0.19)</td>
                                             <td styleCode="Rrule">0.24<br/>(0.20, 0.28)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Famotidine</td>
                                             <td styleCode="Rrule">40 single dose taken 4 hours after RPV</td>
                                             <td styleCode="Rrule">150 single dose<footnoteRef IDREF="T8F1"/>
                                             </td>
                                             <td styleCode="Rrule">24</td>
                                             <td styleCode="Rrule">1.21<br/>(1.06, 1.39)</td>
                                             <td styleCode="Rrule">1.13<br/>(1.01, 1.27)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Ketoconazole</td>
                                             <td styleCode="Rrule">400 once daily</td>
                                             <td styleCode="Rrule">150 once daily<footnoteRef IDREF="T8F1"/>
                                             </td>
                                             <td styleCode="Rrule">15</td>
                                             <td styleCode="Rrule">1.30<br/>(1.13, 1.48)</td>
                                             <td styleCode="Rrule">1.49<br/>(1.31, 1.70)</td>
                                             <td styleCode="Rrule">1.76<br/>(1.57, 1.97)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Methadone</td>
                                             <td styleCode="Rrule">60â100 once daily, individualized dose</td>
                                             <td styleCode="Rrule">25 once daily<footnoteRef IDREF="T8F2"/>
                                             </td>
                                             <td styleCode="Rrule">12</td>
                                             <td styleCode="Rrule">â<footnoteRef IDREF="T8F3"/>
                                             </td>
                                             <td styleCode="Rrule">â<footnoteRef IDREF="T8F3"/>
                                             </td>
                                             <td styleCode="Rrule">â<footnoteRef IDREF="T8F3"/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Ledipasvir/Sofosbuvir</td>
                                             <td styleCode="Rrule">90/400 once daily</td>
                                             <td styleCode="Rrule">25 once daily<footnote ID="T8F4">Study conducted with ODEFSEY (FTC/RPV/TAF).</footnote>
                                             </td>
                                             <td styleCode="Rrule">42</td>
                                             <td styleCode="Rrule">0.97<br/>(0.92, 1.02)</td>
                                             <td styleCode="Rrule">0.95<br/>(0.91, 0.98)</td>
                                             <td styleCode="Rrule">0.93<br/>(0.89, 0.97)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Omeprazole</td>
                                             <td styleCode="Rrule">20 once daily</td>
                                             <td styleCode="Rrule">25 single dose<footnoteRef IDREF="T8F2"/>
                                             </td>
                                             <td styleCode="Rrule">15</td>
                                             <td styleCode="Rrule">0.30<br/>(0.24, 0.38)</td>
                                             <td styleCode="Rrule">0.35<br/>(0.28, 0.44)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Rifabutin</td>
                                             <td styleCode="Rrule">300 once daily</td>
                                             <td styleCode="Rrule">25 once daily<footnoteRef IDREF="T8F2"/>
                                             </td>
                                             <td styleCode="Rrule">18</td>
                                             <td styleCode="Rrule">0.69<br/>(0.62, 0.76)</td>
                                             <td styleCode="Rrule">0.58<br/>(0.52, 0.65)</td>
                                             <td styleCode="Rrule">0.52<br/>(0.46, 0.59)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Rifampin</td>
                                             <td styleCode="Rrule">600 once daily</td>
                                             <td styleCode="Rrule">150 once daily<footnoteRef IDREF="T8F1"/>
                                             </td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">0.31<br/>(0.27, 0.36)</td>
                                             <td styleCode="Rrule">0.20<br/>(0.18, 0.23)</td>
                                             <td styleCode="Rrule">0.11<br/>(0.10, 0.13)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Simeprevir</td>
                                             <td styleCode="Rrule">25 once daily</td>
                                             <td styleCode="Rrule">150 once daily<footnoteRef IDREF="T8F2"/>
                                             </td>
                                             <td styleCode="Rrule">23</td>
                                             <td styleCode="Rrule">1.04<br/>(0.95, 1.30)</td>
                                             <td styleCode="Rrule">1.12<br/>(1.05, 1.19)</td>
                                             <td styleCode="Rrule">1.25<br/>(1.16, 1.35)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Sildenafil</td>
                                             <td styleCode="Rrule">50 single dose</td>
                                             <td styleCode="Rrule">75 once daily<footnoteRef IDREF="T8F1"/>
                                             </td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">0.92<br/>(0.85, 0.99)</td>
                                             <td styleCode="Rrule">0.98<br/>(0.92, 1.05)</td>
                                             <td styleCode="Rrule">1.04<br/>(0.98, 1.09)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Sofosbuvir/velpatasvir</td>
                                             <td styleCode="Rrule">400/100 once daily</td>
                                             <td styleCode="Rrule">10 once daily<footnote ID="T8F5">Study conducted with FTC/RPV/TDF.</footnote>
                                             </td>
                                             <td styleCode="Rrule">24</td>
                                             <td styleCode="Rrule">0.93<br/>(0.88,0.98)</td>
                                             <td styleCode="Rrule">0.95<br/>(0.90, 1.00)</td>
                                             <td styleCode="Rrule">0.96<br/>(0.90,1.03)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Sofosbuvir/velpatasvir/voxilaprevir</td>
                                             <td styleCode="Rrule">400/100/100 + 100 voxilaprevir<footnote ID="K5502">Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV patients.</footnote> once daily</td>
                                             <td styleCode="Rrule">25 once daily<footnoteRef IDREF="T8F4"/>
                                             </td>
                                             <td styleCode="Rrule">30</td>
                                             <td styleCode="Rrule">0.79<br/>(0.74, 0.84)</td>
                                             <td styleCode="Rrule">0.80<br/>(0.76, 0.85)</td>
                                             <td styleCode="Rrule">0.82<br/>(0.77, 0.87)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <table width="85%">
                                       <caption>Table 10 	Changes in Pharmacokinetic Parameters for TAF in the Presence of the Coadministered Drug in Healthy Participants</caption>
                                       <col width="17%" align="left" valign="middle"/>
                                       <col width="17%" align="center" valign="middle"/>
                                       <col width="12%" align="center" valign="middle"/>
                                       <col width="6%" align="center" valign="middle"/>
                                       <col width="16%" align="center" valign="middle"/>
                                       <col width="16%" align="center" valign="middle"/>
                                       <col width="16%" align="center" valign="middle"/>
                                       <thead>
                                          <tr styleCode="Botrule">
                                             <th rowspan="2" align="center" styleCode="Lrule Rrule">Coadministered Drug</th>
                                             <th rowspan="2" styleCode="Rrule">Dose of Coadministered Drug (mg)</th>
                                             <th rowspan="2" styleCode="Rrule">TAF (mg)</th>
                                             <th rowspan="2" styleCode="Rrule">N</th>
                                             <th colspan="3" styleCode="Rrule">Mean Ratio of Tenofovir Alafenamide  Pharmacokinetic Parameters (90% CI);<br/>No Effect = 1.00</th>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <th align="center" styleCode="Rrule">C<sub>max</sub>
                                             </th>
                                             <th styleCode="Rrule">AUC</th>
                                             <th styleCode="Rrule">C<sub>min</sub>
                                             </th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td colspan="7" align="left" valign="top">CI=Confidence Interval; N=maximum number of participants with data; NA=Not Available</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Cobicistat<footnote ID="K5618">Increases TAF exposure via inhibition of intestinal P-glycoprotein. </footnote>
                                             </td>
                                             <td styleCode="Rrule">150 once daily</td>
                                             <td styleCode="Rrule">8 once daily</td>
                                             <td styleCode="Rrule">12</td>
                                             <td styleCode="Rrule">2.83<br/>(2.20, 3.65)</td>
                                             <td styleCode="Rrule">2.65<br/>(2.29, 3.07)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Ledipasvir/Sofosbuvir</td>
                                             <td styleCode="Rrule">90/400 once daily</td>
                                             <td styleCode="Rrule">25 once daily<footnote ID="T9F3">Study conducted with ODEFSEY (FTC/RPV/TAF).</footnote>
                                             </td>
                                             <td styleCode="Rrule">42</td>
                                             <td styleCode="Rrule">1.03<br/>(0.94, 1.14)</td>
                                             <td styleCode="Rrule">1.32<br/>(1.25, 1.40)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Sofosbuvir/velpatasvir/voxilaprevir</td>
                                             <td styleCode="Rrule">400/100/100 + 100 voxilaprevir<footnote ID="K5685">Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in patients with HCV.</footnote> once daily</td>
                                             <td styleCode="Rrule">25 once daily<footnoteRef IDREF="T9F3"/>
                                             </td>
                                             <td styleCode="Rrule">30</td>
                                             <td styleCode="Rrule">1.32<br/>(1.17, 1.48)</td>
                                             <td styleCode="Rrule">1.52<br/>(1.43,1.61)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <table width="85%">
                                       <caption>Table 11	Changes in Pharmacokinetic Parameters for Coadministered Drugs in the Presence of RPV in Healthy Participants</caption>
                                       <col width="17%" align="left" valign="top"/>
                                       <col width="17%" align="center" valign="middle"/>
                                       <col width="12%" align="center" valign="middle"/>
                                       <col width="6%" align="center" valign="middle"/>
                                       <col width="16%" align="center" valign="middle"/>
                                       <col width="16%" align="center" valign="middle"/>
                                       <col width="16%" align="center" valign="middle"/>
                                       <thead>
                                          <tr>
                                             <th rowspan="2" align="center" styleCode="Lrule Rrule Botrule" valign="middle">Coadministered Drug</th>
                                             <th colspan="2" styleCode="Rrule Botrule" valign="bottom">Dose/Schedule</th>
                                             <th styleCode="Rrule"/>
                                             <th colspan="3" styleCode="Rrule Botrule">Mean Ratio  of Coadministered  Drug Pharmacokinetic Parameters With/Without RPV (90% CI); <br/>No Effect  = 1.00</th>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <th align="center" styleCode="Rrule">Coadministered Drug (mg)</th>
                                             <th styleCode="Rrule">RPV (mg)</th>
                                             <th styleCode="Rrule" valign="top">N</th>
                                             <th styleCode="Rrule">C<sub>max</sub>
                                             </th>
                                             <th styleCode="Rrule">AUC</th>
                                             <th styleCode="Rrule">C<sub>min</sub>
                                             </th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td colspan="7" align="left" valign="top">CI=Confidence Interval; N=maximum number of participants with data; NA=Not Available</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="middle">Acetaminophen</td>
                                             <td styleCode="Rrule">500 single dose</td>
                                             <td styleCode="Rrule">150 once daily<footnote ID="T10F1">25 mg, 75 mg, and 150 mg of RPV is 1, 3, and 6 times the recommended dose of RPV in ODEFSEY, respectively.</footnote>
                                             </td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">0.97<br/>(0.86, 1.10)</td>
                                             <td styleCode="Rrule">0.92<br/>(0.85, 0.99)</td>
                                             <td styleCode="Rrule" valign="bottom">NA</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Atorvastatin</td>
                                             <td rowspan="3" styleCode="Rrule Botrule">40 once daily</td>
                                             <td rowspan="3" styleCode="Rrule Botrule">150 once daily<footnoteRef IDREF="T10F1"/>
                                             </td>
                                             <td rowspan="3" styleCode="Rrule Botrule">16</td>
                                             <td styleCode="Rrule">1.35<br/>(1.08, 1.68)</td>
                                             <td styleCode="Rrule">1.04<br/>(0.97, 1.12)</td>
                                             <td styleCode="Rrule" valign="top">0.85<br/>(0.69, 1.03)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">2-hydroxy-atorvastatin</td>
                                             <td styleCode="Rrule">1.58<br/>(1.33, 1.87)</td>
                                             <td styleCode="Rrule">1.39<br/>(1.29, 1.50)</td>
                                             <td styleCode="Rrule">1.32<br/>(1.10, 1.58)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">4-hydroxy-atorvastatin</td>
                                             <td styleCode="Rrule">1.28<br/>(1.15, 1.43)</td>
                                             <td styleCode="Rrule">1.23<br/>(1.13, 1.33)</td>
                                             <td styleCode="Rrule" valign="top">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="middle">Chlorzoxazone</td>
                                             <td styleCode="Rrule">500 single dose taken 2 hours after RPV</td>
                                             <td styleCode="Rrule">150 once daily<footnoteRef IDREF="T10F1"/>
                                             </td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">0.98<br/>(0.85, 1.13)</td>
                                             <td styleCode="Rrule">1.03<br/>(0.95, 1.13)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="middle">Digoxin</td>
                                             <td styleCode="Rrule">0.5 single dose</td>
                                             <td styleCode="Rrule">25 once daily<footnote ID="T10F2">Study conducted with RPV.</footnote>
                                             </td>
                                             <td styleCode="Rrule">22</td>
                                             <td styleCode="Rrule">1.06<br/>(0.97, 1.17)</td>
                                             <td styleCode="Rrule">0.98<br/>(0.93, 1.04)<footnote ID="T10F3">AUC<sub>(0âlast)</sub>. </footnote>
                                             </td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule" valign="top">Ethinylestradiol</td>
                                             <td styleCode="Rrule" valign="top">0.035 once daily</td>
                                             <td rowspan="2" styleCode="Rrule Botrule">25 once daily<footnoteRef IDREF="T10F2"/>
                                             </td>
                                             <td rowspan="2" styleCode="Rrule Botrule">17</td>
                                             <td styleCode="Rrule">1.17<br/>(1.06, 1.30)</td>
                                             <td styleCode="Rrule">1.14<br/>(1.10, 1.19)</td>
                                             <td styleCode="Rrule">1.09<br/>(1.03, 1.16)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="middle">Norethindrone</td>
                                             <td styleCode="Rrule">1 mg once daily</td>
                                             <td styleCode="Rrule">0.94<br/>(0.83, 1.06)</td>
                                             <td styleCode="Rrule">0.89<br/>(0.84, 0.94)</td>
                                             <td styleCode="Rrule">0.99<br/>(0.90, 1.08)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="middle">Ketoconazole</td>
                                             <td styleCode="Rrule">400 once daily</td>
                                             <td styleCode="Rrule">150 once daily<footnoteRef IDREF="T10F1"/>
                                             </td>
                                             <td styleCode="Rrule">14</td>
                                             <td styleCode="Rrule">0.85<br/>(0.80, 0.90)</td>
                                             <td styleCode="Rrule">0.76<br/>(0.70, 0.82)</td>
                                             <td styleCode="Rrule">0.34<br/>(0.25, 0.46)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="middle">Ledipasvir</td>
                                             <td styleCode="Rrule">90 once daily</td>
                                             <td styleCode="Rrule">25 once daily<footnote ID="T10F4">Study conducted with ODEFSEY (FTC/RPV/TAF).</footnote>
                                             </td>
                                             <td styleCode="Rrule">41</td>
                                             <td styleCode="Rrule">1.01<br/>(0.97, 1.05)</td>
                                             <td styleCode="Rrule">1.02<br/>(0.97, 1.06)</td>
                                             <td styleCode="Rrule">1.02<br/>(0.98, 1.07)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Sofosbuvir</td>
                                             <td rowspan="2" styleCode="Rrule Botrule">400 once daily</td>
                                             <td rowspan="2" styleCode="Rrule Botrule">25 once daily<footnoteRef IDREF="T10F4"/>
                                             </td>
                                             <td rowspan="2" styleCode="Rrule Botrule">41</td>
                                             <td styleCode="Rrule">0.96<br/>(0.89, 1.04)</td>
                                             <td styleCode="Rrule">1.05<br/>(1.01, 1.09)</td>
                                             <td styleCode="Rrule" valign="top">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="middle">GS-331007<footnote ID="T10F6">The predominant circulating nucleoside metabolite of sofosbuvir.</footnote>
                                             </td>
                                             <td styleCode="Rrule">1.08<br/>(1.05, 1.11)</td>
                                             <td styleCode="Rrule">1.08<br/>(1.06, 1.10)</td>
                                             <td styleCode="Rrule">1.10<br/>(1.07, 1.12)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">R(-) methadone</td>
                                             <td rowspan="2" styleCode="Rrule Botrule">60â100 once daily, individualized dose</td>
                                             <td rowspan="2" styleCode="Rrule Botrule">25 once daily<footnoteRef IDREF="T10F2"/>
                                             </td>
                                             <td rowspan="2" styleCode="Rrule Botrule">13</td>
                                             <td styleCode="Rrule">0.86<br/>(0.78, 0.95)</td>
                                             <td styleCode="Rrule">0.84<br/>(0.74, 0.95)</td>
                                             <td styleCode="Rrule">0.78<br/>(0.67, 0.91)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="middle">S(+) methadone</td>
                                             <td styleCode="Rrule">0.87<br/>(0.78, 0.97)</td>
                                             <td styleCode="Rrule">0.84<br/>(0.74, 0.96)</td>
                                             <td styleCode="Rrule">0.79<br/>(0.67, 0.92)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="middle">Metformin</td>
                                             <td styleCode="Rrule">850 single dose</td>
                                             <td styleCode="Rrule">25 once daily<footnoteRef IDREF="T10F2"/>
                                             </td>
                                             <td styleCode="Rrule">20</td>
                                             <td styleCode="Rrule">1.02<br/>(0.95, 1.10)</td>
                                             <td styleCode="Rrule">0.97<br/>(0.90,1.06)<footnote ID="T10F5">N (maximum number of participants with data for AUC<sub>(0ââ)</sub>=15)</footnote>
                                             </td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Rifampin</td>
                                             <td rowspan="2" styleCode="Rrule Botrule">600 once daily</td>
                                             <td rowspan="2" styleCode="Rrule Botrule">150 once daily<footnoteRef IDREF="T10F1"/>
                                             </td>
                                             <td rowspan="2" styleCode="Rrule Botrule">16</td>
                                             <td styleCode="Rrule">1.02<br/>(0.93, 1.12)</td>
                                             <td styleCode="Rrule">0.99<br/>(0.92, 1.07)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">25-desacetylrifampin</td>
                                             <td styleCode="Rrule">1.00<br/>(0.87, 1.15)</td>
                                             <td styleCode="Rrule">0.91<br/>(0.77, 1.07)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="middle">Simeprevir</td>
                                             <td styleCode="Rrule">150 once daily</td>
                                             <td styleCode="Rrule">25 once daily<footnoteRef IDREF="T10F2"/>
                                             </td>
                                             <td styleCode="Rrule">21</td>
                                             <td styleCode="Rrule">1.10<br/>(0.97, 1.26)</td>
                                             <td styleCode="Rrule">1.06<br/>(0.94, 1.19)</td>
                                             <td styleCode="Rrule">0.96<br/>(0.83, 1.11)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Sildenafil</td>
                                             <td rowspan="2" styleCode="Rrule Botrule">50 single dose</td>
                                             <td rowspan="2" styleCode="Rrule Botrule">75 once daily<footnoteRef IDREF="T10F1"/>
                                             </td>
                                             <td rowspan="2" styleCode="Rrule Botrule">16</td>
                                             <td styleCode="Rrule">0.93<br/>(0.80, 1.08)</td>
                                             <td styleCode="Rrule">0.97<br/>(0.87, 1.08)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="italics">N</content>-desmethyl-sildenafil</td>
                                             <td styleCode="Rrule">0.90<br/>(0.80, 1.02)</td>
                                             <td styleCode="Rrule">0.92<br/>(0.85, 0.99)<footnoteRef IDREF="T10F3"/>
                                             </td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Sofosbuvir<br/>
                                                <br/>GS-331007<footnoteRef IDREF="T10F6"/>
                                             </td>
                                             <td styleCode="Rrule">400 once daily</td>
                                             <td styleCode="Rrule">25 once daily<footnote ID="T10F7">Study conducted with FTC/RPV/TDF.</footnote>
                                             </td>
                                             <td styleCode="Rrule">24<br/>
                                             </td>
                                             <td styleCode="Rrule">1.09<br/>(0.95, 1.25)<br/>0.96<br/>(0.90, 1.01)</td>
                                             <td styleCode="Rrule">1.16<br/>(1.10, 1.24)<br/>1.04<br/>(1.00, 1.07)</td>
                                             <td styleCode="Rrule">
                                                <br/>NA<br/>1.12<br/>(1.07, 1.17)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="middle">Velpatasvir</td>
                                             <td styleCode="Rrule">100 once daily</td>
                                             <td styleCode="Rrule">25 once daily<footnoteRef IDREF="T10F7"/>
                                             </td>
                                             <td styleCode="Rrule">24</td>
                                             <td styleCode="Rrule">0.96<br/>(0.85, 1.10)</td>
                                             <td styleCode="Rrule">0.99<br/>(0.88, 1.11)</td>
                                             <td styleCode="Rrule">1.02<br/>(0.91, 1.15)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule" valign="middle">Sofosbuvir</td>
                                             <td rowspan="2" styleCode="Rrule Botrule">400 once daily</td>
                                             <td rowspan="2" styleCode="Rrule Botrule">25 once daily<footnoteRef IDREF="T10F4"/>
                                             </td>
                                             <td rowspan="2" styleCode="Rrule Botrule">30</td>
                                             <td styleCode="Rrule">0.95<br/>(0.86, 1.05)</td>
                                             <td styleCode="Rrule">1.01<br/>(0.97, 1.06)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">GS-331007<footnoteRef IDREF="T10F6"/>
                                             </td>
                                             <td styleCode="Rrule">1.02<br/>(0.98, 1.06)</td>
                                             <td styleCode="Rrule">1.04<br/>(1.01, 1.06)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="middle">Velpatasvir</td>
                                             <td styleCode="Rrule">100 once daily</td>
                                             <td styleCode="Rrule">25 once daily<footnoteRef IDREF="T10F4"/>
                                             </td>
                                             <td styleCode="Rrule">30</td>
                                             <td styleCode="Rrule">1.05<br/>(0.96, 1.16)</td>
                                             <td styleCode="Rrule">1.01<br/>(0.94, 1.07)</td>
                                             <td styleCode="Rrule">1.01<br/>(0.95, 1.09)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule" valign="middle">Voxilaprevir</td>
                                             <td styleCode="Rrule">100 + 100 once daily</td>
                                             <td styleCode="Rrule">25 once daily<footnoteRef IDREF="T10F4"/>
                                             </td>
                                             <td styleCode="Rrule">30</td>
                                             <td styleCode="Rrule">0.96<br/>(0.84, 1.11)</td>
                                             <td styleCode="Rrule">0.94<br/>(0.84, 1.05)</td>
                                             <td styleCode="Rrule">1.02<br/>(0.92, 1.12)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <table width="85%">
                                       <caption>Table 12	Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of TAF in Healthy Participants</caption>
                                       <col width="17%" align="left" valign="middle"/>
                                       <col width="17%" align="center" valign="middle"/>
                                       <col width="12%" align="center" valign="middle"/>
                                       <col width="6%" align="center" valign="middle"/>
                                       <col width="16%" align="center" valign="middle"/>
                                       <col width="16%" align="center" valign="middle"/>
                                       <col width="16%" align="center" valign="middle"/>
                                       <thead>
                                          <tr styleCode="Botrule">
                                             <th rowspan="2" align="center" styleCode="Lrule Rrule">Coadministered Drug</th>
                                             <th rowspan="2" styleCode="Rrule">Dose of Coadministered Drug (mg)</th>
                                             <th rowspan="2" styleCode="Rrule">TAF (mg)</th>
                                             <th rowspan="2" styleCode="Rrule">N</th>
                                             <th colspan="3" styleCode="Rrule">Mean Ratio of Coadministered Drug Pharmacokinetic Parameters (90% CI); <br/>No Effect = 1.00</th>
                                          </tr>
                                          <tr>
                                             <th align="center" styleCode="Rrule">C<sub>max</sub>
                                             </th>
                                             <th styleCode="Rrule">AUC</th>
                                             <th styleCode="Rrule">C<sub>min</sub>
                                             </th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td colspan="7" align="left" valign="top">CI=Confidence Interval; N=maximum number of participants with data; NA=Not Available</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td rowspan="2" styleCode="Lrule Rrule">Midazolam<footnote ID="T11F1">A sensitive CYP3A4 substrate.</footnote>
                                             </td>
                                             <td styleCode="Rrule">2.5 single dose, orally</td>
                                             <td rowspan="2" styleCode="Rrule">25 once daily<footnote ID="T11F2">Study conducted with TAF.</footnote>
                                                <br/>
                                             </td>
                                             <td rowspan="2" styleCode="Rrule">18<br/>
                                             </td>
                                             <td styleCode="Rrule">1.02<br/>(0.92, 1.13)</td>
                                             <td styleCode="Rrule">1.13<br/>(1.04, 1.23)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="center" styleCode="Rrule">1 single dose, IV</td>
                                             <td styleCode="Rrule">0.99<br/>(0.89, 1.11)</td>
                                             <td styleCode="Rrule">1.08<br/>(1.04, 1.13)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Ledipasvir<footnote ID="T11F3">Study conducted with ODEFSEY (FTC/RPV/TAF).</footnote>
                                             </td>
                                             <td rowspan="3" styleCode="Rrule">90/400 once daily<br/>
                                             </td>
                                             <td rowspan="3" styleCode="Rrule">25 once daily<footnoteRef IDREF="T11F3"/>
                                                <br/>
                                             </td>
                                             <td rowspan="3" styleCode="Rrule">41</td>
                                             <td styleCode="Rrule">1.01<br/>(0.97, 1.05)</td>
                                             <td styleCode="Rrule">1.02<br/>(0.97, 1.06)</td>
                                             <td styleCode="Rrule">1.02<br/>(0.98,1.07)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Sofosbuvir<footnoteRef IDREF="T11F3"/>
                                             </td>
                                             <td styleCode="Rrule">0.96<br/>(0.89, 1.04)</td>
                                             <td styleCode="Rrule">1.05<br/>(1.01, 1.09)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">GS-331007<footnoteRef IDREF="T11F3"/>
                                                <sup>,</sup>
                                                <footnote ID="T11F4">The predominant circulating nucleoside metabolite of sofosbuvir.</footnote>
                                             </td>
                                             <td styleCode="Rrule">1.08<br/>(1.05, 1.11)</td>
                                             <td styleCode="Rrule">1.08<br/>(1.06, 1.10)</td>
                                             <td styleCode="Rrule">1.10 (1.07, 1.12)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Norelgestromin</td>
                                             <td rowspan="3" styleCode="Rrule">norgestimate 0.180/0.215/0.250 once daily/ethinyl estradiol 0.025 once daily</td>
                                             <td rowspan="3" styleCode="Rrule">25 once daily<footnote ID="K6812">Study conducted with FTC/TAF.</footnote>
                                             </td>
                                             <td rowspan="3" styleCode="Rrule">29</td>
                                             <td styleCode="Rrule">1.17<br/>(1.07,1.26)</td>
                                             <td styleCode="Rrule">1.12<br/>(1.07, 1.17)</td>
                                             <td styleCode="Rrule">1.16<br/>(1.08,1.24)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Norgestrel</td>
                                             <td styleCode="Rrule">1.10<br/>(1.02, 1.18)</td>
                                             <td styleCode="Rrule">1.09<br/>(1.01, 1.18)</td>
                                             <td styleCode="Rrule">1.11<br/>(1.03,1.20)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Ethinyl estradiol</td>
                                             <td styleCode="Rrule">1.22<br/>(1.15, 1.29)</td>
                                             <td styleCode="Rrule">1.11<br/>(1.07, 1.16)</td>
                                             <td styleCode="Rrule">1.02<br/>(0.93,1.12)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule Botrule">Sofosbuvir</td>
                                             <td rowspan="2" styleCode="Rrule Botrule">400 once daily</td>
                                             <td rowspan="4" styleCode="Rrule Botrule">25 once daily<footnoteRef IDREF="T11F3"/>
                                             </td>
                                             <td rowspan="4" styleCode="Rrule Botrule">30</td>
                                             <td styleCode="Rrule">0.95<br/>(0.86, 1.05)</td>
                                             <td styleCode="Rrule">1.01<br/>(0.97, 1.06)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule Botrule">GS-331007<footnoteRef IDREF="T11F4"/>
                                             </td>
                                             <td styleCode="Rrule">1.02<br/>(0.98, 1.06)</td>
                                             <td styleCode="Rrule">1.04<br/>(1.01, 1.06)</td>
                                             <td styleCode="Rrule">NA</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule Botrule">Velpatasvir</td>
                                             <td styleCode="Rrule Botrule">100 once daily</td>
                                             <td styleCode="Rrule">1.05<br/>(0.96, 1.16)</td>
                                             <td styleCode="Rrule">1.01<br/>(0.94, 1.07)</td>
                                             <td styleCode="Rrule">1.01<br/>(0.95,1.09)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Voxilaprevir</td>
                                             <td styleCode="Rrule">100 + 100 once daily</td>
                                             <td styleCode="Rrule">0.96<br/>(0.84, 1.11)</td>
                                             <td styleCode="Rrule">0.94<br/>(0.84, 1.05)</td>
                                             <td styleCode="Rrule">1.02<br/>(0.92,1.12)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="74570942-8bcb-48a1-8c46-faf231eb0ea5"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <effectiveTime value="20250224"/>
                     <component>
                        <section>
                           <id root="58e92f8e-da3c-494a-807b-790c9996009f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mechanism of Action</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                           <component>
                              <section>
                                 <id root="49e43862-caee-4bf8-9bf6-90f62d2903df"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Emtricitabine:</content> FTC, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 reverse transcriptase (RT) by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination. Emtricitabine 5â²-triphosphate is a weak inhibitor of mammalian DNA polymerases Î±, Î², Æ, and mitochondrial DNA polymerase Î³.</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="5fe5a37f-d24c-4176-90b4-fc90da509016"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Rilpivirine:</content> RPV is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor of HIV-1 and inhibits HIV-1 replication by non-competitive inhibition of HIV-1 RT. RPV does not inhibit the human cellular DNA polymerases Î±, Î², and mitochondrial DNA polymerase Î³.</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="d0f5a460-953d-4ee3-8e24-e3ceeb593486"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Tenofovir Alafenamide:</content> TAF is a phosphonamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analog). Plasma exposure to TAF allows for permeation into cells and then TAF is intracellularly converted to tenofovir through hydrolysis by cathepsin A. Tenofovir is subsequently phosphorylated by cellular kinases to the active metabolite tenofovir diphosphate. Tenofovir diphosphate inhibits HIV-1 replication through incorporation into viral DNA by the HIV reverse transcriptase, which results in DNA chain termination.</paragraph>
                                    <paragraph>Tenofovir has activity against human immunodeficiency virus (HIV-1). Cell culture studies have shown that both tenofovir and FTC can be fully phosphorylated when combined in cells. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase Î³ and there is no evidence of toxicity to mitochondria cell culture.</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="95ba7855-2e47-4ed0-85ee-2e8e7880a47e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Antiviral Activity in Cell Culture</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                           <component>
                              <section>
                                 <id root="ceca64af-7283-4d70-9453-80d9a1887366"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Emtricitabine, Rilpivirine, and Tenofovir Alafenamide:</content> The combinations of FTC, RPV, and TAF were not antagonistic with each other in cell culture combination antiviral activity assays. In addition, FTC, RPV, and TAF were not antagonistic with a panel of representatives from the major classes of approved anti-HIV agents (NNRTIs, NRTIs, INSTIs, and PIs).</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="f6ab3fb1-d9e7-47e6-b54b-5a092f4e39e8"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Emtricitabine:</content> The antiviral activity of FTC against laboratory and clinical isolates of HIV-1 was assessed in T lymphoblastoid cell lines, the MAGI-CCR5 cell line, and primary peripheral blood mononuclear cells (PBMCs). The EC<sub>50</sub> values for FTC were in the range of 1.3â640 nM. FTC displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC<sub>50</sub> values ranged from 7â75 nM) and showed strain-specific activity against HIV-2 (EC<sub>50</sub> values ranged from 7â1500 nM).</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="be412783-abdf-416d-9933-5db38e2b91e2"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Rilpivirine:</content> RPV exhibited activity against laboratory strains of wild-type HIV-1 in an acutely infected T-cell line with a median EC<sub>50</sub> value for HIV-1<sub>IIIB</sub> of 0.73 nM. RPV demonstrated limited activity in cell culture against HIV-2 with a median EC<sub>50</sub> value of 5220 nM (range 2510â10,830 nM). RPV demonstrated antiviral activity against a broad panel of HIV-1 group M (subtype A, B, C, D, F, G, H) primary isolates with EC<sub>50</sub> values ranging from 0.07â1.01 nM and was less active against group O primary isolates with EC<sub>50</sub> values ranging from 2.88â8.45 nM.</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="dbcc49b1-3065-43e0-b1dc-40f0825a9ca9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Tenofovir Alafenamide:</content> The antiviral activity of TAF against laboratory and clinical isolates of HIV-1 subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells and CD4-T lymphocytes. The EC<sub>50</sub> values for TAF ranged from 2.0â14.7 nM.</paragraph>
                                    <paragraph>TAF displayed antiviral activity in cell culture against all HIV-1 groups (M, N, O), including sub-types A, B, C, D, E, F, and G (EC<sub>50</sub> values ranged from 0.10â12.0 nM) and strain specific activity against HIV-2 (EC<sub>50</sub> values ranged from 0.91â2.63 nM).</paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="81a7520b-b2fc-4d9c-aa87-72e6f99e7a68"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Resistance</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                           <component>
                              <section>
                                 <id root="63011f36-75ae-400e-849e-08cdc9c40e71"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Cell Culture</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                                 <component>
                                    <section>
                                       <id root="e215f26f-a606-4edb-b8e9-8c22cdc31b0b"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Emtricitabine:</content> HIV-1 isolates with reduced susceptibility to FTC were selected in cell culture. Reduced susceptibility to FTC was associated with M184V or I substitutions in HIV-1 RT.</paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="0855a402-55e6-42ff-a981-7b35510706e4"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Rilpivirine:</content> RPV-resistant strains were selected in cell culture starting from wild-type HIV-1 of different origins and subtypes as well as NNRTI-resistant HIV-1. The frequently observed amino acid substitutions that emerged and conferred decreased phenotypic susceptibility to RPV included: L100I, K101E, V106I and A, V108I, E138K and G, Q, R, V179F and I, Y181C and I, V189I, G190E, H221Y, F227C, and M230I and L.</paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="60f3d420-f1b7-40d7-9e1d-1802f6dfb6b4"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Tenofovir Alafenamide:</content> HIV-1 isolates with reduced susceptibility to TAF were selected in cell culture. HIV-1 isolates selected by TAF expressed a K65R substitution in HIV-1 RT, sometimes in the presence of S68N or L429I substitutions; in addition, a K70E substitution in HIV-1 RT was observed.</paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="cee25c13-3c73-4ff5-a45e-21c15e7bfb69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Clinical Trials</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250224"/>
                                 <component>
                                    <section>
                                       <id root="d753c0d7-5b89-4ce5-951a-d11784df0695"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline">In Participants With HIV-1 and No Antiretroviral Treatment History</content>
                                          </paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                       <component>
                                          <section>
                                             <id root="2fa3c6b1-c1b9-44b3-94d7-a448bdb099a2"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Emtricitabine and Tenofovir Alafenamide:</content> The resistance profile of ODEFSEY for the treatment of HIV-1 is based on studies of FTC+TAF with EVG+COBI in the treatment of HIV-1<content styleCode="italics">.</content> In a pooled analysis of antiretroviral-naÃ¯ve participants, genotyping was performed on plasma HIV-1 isolates from all participants with HIV-1 RNA greater than 400 copies per mL at confirmed virologic failure, at Week 48, or at time of early study drug discontinuation. Genotypic resistance developed in 7 of 14 evaluable participants. The resistanceâassociated substitutions that emerged were M184V/I (N=7) and K65R (N=1). Three participants had virus with emergent R, H, or E at the polymorphic Q207 residue in reverse transcriptase.</paragraph>
                                             </text>
                                             <effectiveTime value="20250224"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="48ca28fe-8957-42ce-9b72-6e4c971f5270"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Rilpivirine:</content> In the Week 96 pooled resistance analysis for adult participants receiving RPV or efavirenz in combination with FTC/TDF, the emergence of resistance was greater among participants' viruses in the RPV+FTC/TDF arm compared to the efavirenz+FTC/TDF arm and was dependent on baseline viral load. In the Week 96 resistance analysis, 14% (77/550) of the participants in the RPV+FTC/TDF arm and 8% (43/546) of the participants in the efavirenz+FTC/TDF arm qualified for resistance analysis; 61% (47/77) of the participants who qualified for resistance analysis (resistance-analysis participants) in the RPV+FTC/TDF arm had virus with genotypic and/or phenotypic resistance to RPV compared to 42% (18/43) of the resistance-analysis participants in the efavirenz+FTC/TDF arm who had genotypic and/or phenotypic resistance to efavirenz. Moreover, genotypic and/or phenotypic resistance to emtricitabine or tenofovir emerged in viruses from 57% (44/77) of the resistance-analysis participants in the RPV arm compared to 26% (11/43) in the efavirenz arm.</paragraph>
                                                <paragraph>Emerging NNRTI substitutions in the RPV resistance analysis of participants' viruses included V90I, K101E/P/T, E138K/A/Q/G, V179I/L, Y181C/I, V189I, H221Y, F227C/L, and M230L, which were associated with an RPV phenotypic fold change range of 2.6â621. The E138K substitution emerged most frequently during RPV treatment, commonly in combination with the M184I substitution. The emtricitabine and lamivudine resistance-associated substitutions M184I or V and NRTI resistance-associated substitutions (A62V, K65R/N, D67N/G, K70E, Y115F, K219E/R) emerged more frequently in the RPV resistance-analysis participants than in efavirenz resistance-analysis participants<content styleCode="italics">.</content>
                                                </paragraph>
                                                <paragraph>NNRTI- and NRTI-resistance substitutions emerged less frequently in the resistance analysis of viruses from participants with baseline viral loads of less than or equal to 100,000 copies/mL compared to viruses from participants with baseline viral loads of greater than 100,000 copies/mL: 23% (10/44) compared to 77% (34/44) of NNRTI-resistance substitutions and 20% (9/44) compared to 80% (35/44) of NRTI-resistance substitutions. This difference was also observed for the individual emtricitabine/lamivudine and tenofovir resistance substitutions: 22% (9/41) compared to 78% (32/41) for M184I/V and 0% (0/8) compared to 100% (8/8) for K65R/N. Additionally, NNRTI and/or NRTI-resistance substitutions emerged less frequently in the resistance analysis of the viruses from participants with baseline CD4+ cell counts greater than or equal to 200 cells/mm<sup>3</sup> compared to the viruses from participants with baseline CD4+ cell counts less than 200 cells/mm<sup>3</sup>: 32% (14/44) compared to 68% (30/44) of NNRTI-resistance substitutions and 27% (12/44) compared to 73% (32/44) of NRTI-resistance substitutions.</paragraph>
                                             </text>
                                             <effectiveTime value="20250224"/>
                                          </section>
                                       </component>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="690be71a-a2c8-45db-8031-8ecb28cf37b2"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline">In Virologically-Suppressed Participants</content>
                                          </paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                       <component>
                                          <section>
                                             <id root="d0b18fed-e126-4dbd-9221-48da7f8c2437"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Emtricitabine and Tenofovir Alafenamide:</content> One participant was identified with emergent resistance to FTC or TAF (M184M/I) out of 4 virologic failure participants in a clinical study of virologically-suppressed participants who switched from a regimen containing FTC+TDF to FTC+TAF with EVG+COBI (N=799).</paragraph>
                                             </text>
                                             <effectiveTime value="20250224"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="ba624f64-6428-4f99-a105-fc411cf1b775"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Rilpivirine:</content> Through Week 48, 4 participants who switched their protease inhibitor-based regimen to FTC/RPV/TDF (4 of 469 participants, 0.9%) and 1 participant who maintained their regimen (1 of 159 participants, 0.6%) developed genotypic and/or phenotypic resistance to a study drug. All 4 of the participants who had resistance emergence on FTC/RPV/TDF had evidence of FTC resistance and 3 of the participants had evidence of RPV resistance.</paragraph>
                                             </text>
                                             <effectiveTime value="20250224"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="0f2c5681-ea77-4ade-b497-1ebbef55bc1e"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">ODEFSEY:</content> Through Week 48, in participants who switched to ODEFSEY from FTC/RPV/TDF or EFV/FTC/TDF (Trials 1216 (N=316) and 1160 (N=438), respectively), of seven participants who developed virologic failure, three participants had detectable NNRTI and/or NRTI resistance substitutions at virologic failure that were pre-existing in the baseline sample by proviral DNA sequencing; one of these participants resuppressed while maintaining ODEFSEY.</paragraph>
                                             </text>
                                             <effectiveTime value="20250224"/>
                                          </section>
                                       </component>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="9bfb05f8-96c8-447a-b94c-a00ad98c855d"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline">Cross-Resistance</content>
                                          </paragraph>
                                       </text>
                                       <effectiveTime value="20250224"/>
                                       <component>
                                          <section>
                                             <id root="0b939f8c-8e89-4651-b9c1-862b26e5cc98"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Emtricitabine:</content> FTC-resistant viruses with the M184V/I substitution were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir, and zidovudine.</paragraph>
                                                <paragraph>Viruses harboring substitutions conferring reduced susceptibility to stavudine and zidovudineâthymidine analog substitutions (M41L, D67N, K70R, L210W, T215Y/F, K219Q/E), or didanosine (L74V) remained sensitive to FTC. HIV-1 containing the K103N substitution or other substitutions associated with resistance to NNRTIs was susceptible to FTC.</paragraph>
                                             </text>
                                             <effectiveTime value="20250224"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="ac2524e3-f1e7-4a8c-ab4c-a5b11f26e618"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Rilpivirine:</content> Considering all of the available cell culture and clinical data, any of the following amino acid substitutions, when present at baseline, are likely to decrease the antiviral activity of RPV: K101E, K101P, E138A, E138G, E138K, E138R, E138Q, V179L, Y181C, Y181I, Y181V, Y188L, H221Y, F227C, M230I, M230L, and the combination of L100I+K103N.</paragraph>
                                                <paragraph>Cross-resistance in site-directed mutant virus has been observed among NNRTIs. The single NNRTI substitutions K101P, Y181I, and Y181V conferred 52 times, 15 times, and 12 times decreased susceptibility to RPV, respectively. The combination of E138K and M184I showed 6.7 times reduced susceptibility to RPV compared to 2.8 times for E138K alone. The K103N substitution did not show reduced susceptibility to RPV by itself. However, the combination of L100I and K103N resulted in a 7 times reduced susceptibility to RPV. In another study, the Y188L substitution resulted in a reduced susceptibility to RPV of 9 times for clinical isolates and 6 times for site-directed mutants. Combinations of 2 or 3 NNRTI resistance-associated substitutions gave decreased susceptibility to RPV (fold change range of 3.7â554) in 38% and 66% of mutants, respectively.</paragraph>
                                                <paragraph>Cross-resistance to efavirenz, etravirine, and/or nevirapine is likely after virologic failure and development of RPV resistance.</paragraph>
                                             </text>
                                             <effectiveTime value="20250224"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="99d9ec87-2161-4f94-bc5d-0f156ac86b94"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Tenofovir Alafenamide:</content> Tenofovir resistance substitutions K65R and K70E result in reduced susceptibility to abacavir, didanosine, emtricitabine, lamivudine, and tenofovir.</paragraph>
                                                <paragraph>HIV-1 with multiple thymidine analog substitutions (M41L, D67N, K70R, L210W, T215F/Y, K219Q/E/N/R), or multinucleoside resistant HIV-1 with a T69S double insertion mutation or with a Q151M substitution complex including K65R showed reduced susceptibility to TAF in cell culture.</paragraph>
                                             </text>
                                             <effectiveTime value="20250224"/>
                                          </section>
                                       </component>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="7d839277-3c73-41ff-805f-31e2b35dcd2f"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250224"/>
               <component>
                  <section ID="S13.1">
                     <id root="a7efe04d-fef5-45f7-bf0e-46609242cd37"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250224"/>
                     <component>
                        <section>
                           <id root="313c814a-c6eb-470b-8d1d-7a29514ffb1f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Emtricitabine:</content> In long-term carcinogenicity studies of FTC, no drug-related increases in tumor incidence were found in mice at doses up to 750 mg per kg per day (23 times the human systemic exposure at the recommended dose of 200 mg per day in ODEFSEY) or in rats at doses up to 600 mg per kg per day (28 times the human systemic exposure at the recommended dose in ODEFSEY).</paragraph>
                              <paragraph>FTC was not genotoxic in the reverse mutation bacterial test (Ames test), mouse lymphoma or mouse micronucleus assays.</paragraph>
                              <paragraph>FTC did not affect fertility in male rats at approximately 140 times or in male and female mice at approximately 60 times higher exposures (AUC) than in humans given the recommended 200 mg daily dose in ODEFSEY. Fertility was normal in the offspring of mice exposed daily from before birth (in utero) through sexual maturity at daily exposures (AUC) of approximately 60 times higher than human exposures at the recommended 200 mg daily dose in ODEFSEY.</paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="414fb39f-70cf-4066-aeaf-6b1024112e8c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Rilpivirine:</content> RPV was evaluated for carcinogenic potential by oral gavage administration to mice and rats up to 104 weeks. Daily doses of 20, 60, and 160 mg per kg per day were administered to mice and doses of 40, 200, 500, and 1500 mg per kg per day were administered to rats. In rats, there were no drug-related neoplasms. In mice, RPV was positive for hepatocellular neoplasms in both males and females. The observed hepatocellular findings in mice may be rodent-specific. At the lowest tested doses in the carcinogenicity studies, the systemic exposures (based on AUC) to RPV were 21 times (mice) and 3 times (rats) relative to those observed in humans at the recommended dose (25 mg once daily) in ODEFSEY.</paragraph>
                              <paragraph>RPV has tested negative in the absence and presence of a metabolic activation system, in the in vitro Ames reverse mutation assay and in vitro clastogenicity mouse lymphoma assay. RPV did not induce chromosomal damage in the in vivo micronucleus test in mice<content styleCode="italics">.</content>
                              </paragraph>
                              <paragraph>In a study conducted in rats, there were no effects on mating or fertility with RPV up to 400 mg per kg per day, a dose of RPV that showed maternal toxicity. This dose is associated with an exposure that is approximately 40 times higher than the exposure in humans at the recommended dose of 25 mg once daily in ODEFSEY.</paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2835f3c4-9679-46f6-a6e1-fa5a6850f279"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Tenofovir Alafenamide:</content> Since TAF is rapidly converted to tenofovir and a lower tenofovir exposure in rats and mice was observed after TAF administration compared to TDF administration, carcinogenicity studies were conducted only with TDF. Long-term oral carcinogenicity studies of TDF in mice and rats were carried out at exposures up to approximately 10 times (mice) and 4 times (rats) those observed in humans at the recommended dose of TDF (300 mg) for HIV-1 infection. The tenofovir exposure in these studies was approximately 167 times (mice) and 55 times (rat) those observed in humans after administration of the daily recommended dose of ODEFSEY. At the high dose in female mice, liver adenomas were increased at tenofovir exposures approximately 10 times (300 mg TDF) and 167 times (ODEFSEY) the exposure observed in humans. In rats, the study was negative for carcinogenic findings.</paragraph>
                              <paragraph>TAF was not genotoxic in the reverse mutation bacterial test (Ames test), mouse lymphoma or rat micronucleus assays.</paragraph>
                              <paragraph>There were no effects on fertility, mating performance or early embryonic development when TAF was administered to male rats at a dose equivalent to 62 times the human dose based on body surface area comparisons for 28 days prior to mating and to female rats for 14 days prior to mating through Day 7 of gestation.</paragraph>
                           </text>
                           <effectiveTime value="20250224"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="f153cb7d-b6c6-4dbe-a88e-673e8b50fee5"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Minimal to slight infiltration of mononuclear cells in the posterior uvea was observed in dogs with similar severity after three- and nine-month administration of TAF; reversibility was seen after a three-month recovery period. No eye toxicity was observed in the dog at systemic exposures of 5 (TAF) and 15 (tenofovir) times the exposure seen in humans at the recommended daily TAF dose in ODEFSEY.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="e689bfdd-fe3b-459a-818e-a76894b1bb82"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250224"/>
               <component>
                  <section ID="S14.1">
                     <id root="ba5e6b5b-a746-417d-9210-e3ed571076b1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 	Clinical Trial Results in HIV-1 Virologically-Suppressed Subjects Who Switched to ODEFSEY</title>
                     <text>
                        <paragraph>In Trial 1216, the efficacy and safety of switching from emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) to ODEFSEY were evaluated in a randomized, double-blind study of virologically-suppressed adults with HIV-1. Participants were suppressed (HIV-1 RNA &lt;50 copies/mL) on their baseline regimen of FTC/RPV/TDF for at least 6 months and had no documented resistance mutations to FTC, TAF, or RPV prior to study entry.  Participants were randomized in a 1:1 ratio to either switch to ODEFSEY (N=316) once daily or stay on FTC/RPV/TDF (N=314) once daily.  Participants had a mean age of 45 years (range: 23â72), 90% were male, 75% were White, and 19% were Black.  The mean baseline CD4+ cell count was 709 cells/mm<sup>3</sup> (range: 104â2527).</paragraph>
                        <paragraph>In Trial 1160, the efficacy and safety of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to ODEFSEY were evaluated in a randomized, double-blind study of virologically-suppressed adults with HIV-1.  Participants were stably suppressed (HIV-1 RNA &lt;50 copies/mL) on their baseline regimen of EFV/FTC/TDF for at least 6 months and had no documented resistance mutations to FTC, TAF, or RPV prior to study entry.  Participants were randomized in a 1:1 ratio to either switch to ODEFSEY (N=438) once daily or stay on EFV/FTC/TDF (N=437) once daily.  Participants had a mean age of 48 years (range: 19â76), 87% were male, 67% were White, and 27% were Black.  The mean baseline CD4+ cell count was 700 cells/mm<sup>3</sup> (range: 140â1862).</paragraph>
                        <paragraph>Treatment outcomes of Trials 1216 and 1160 are presented in Table 13.</paragraph>
                        <table width="90%">
                           <caption>Table 13 	Virologic Outcomes of Trials 1216 and 1160 at Week 48<footnote ID="K7594">Week 48 window was between Day 295 and 378 (inclusive).</footnote> in Virologically-Suppressed Participants who Switched to ODEFSEY </caption>
                           <col width="20%" align="left" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule"/>
                                 <th colspan="2" styleCode="Rrule">Study 1216</th>
                                 <th colspan="2" styleCode="Rrule">Study 1160</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th align="center" styleCode="Rrule">ODEFSEY<br/>(N=316)</th>
                                 <th styleCode="Rrule">FTC/RPV/TDF<br/>(N=313)<footnote ID="K7644">One subject who was not on FTC/RPV/TDF prior to screening was excluded from the efficacy analysis.</footnote>
                                 </th>
                                 <th styleCode="Rrule">ODEFSEY<br/>(N=438)</th>
                                 <th styleCode="Rrule">EFV/FTC/TDF<br/> (N=437)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">HIV-1 RNA &lt;50 copies/mL</content>
                                 </td>
                                 <td styleCode="Rrule">94%</td>
                                 <td styleCode="Rrule">94%</td>
                                 <td styleCode="Rrule">90%</td>
                                 <td styleCode="Rrule">92%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">HIV-1 RNA â¥50 copies/mL<footnote ID="K7683">Included participants who had HIV-1 RNA â¥50 copies/mL in the Week 48 window; participants who discontinued early due to lack or loss of efficacy; participants who discontinued for reasons other than lack or loss of efficacy and at the time of discontinuation had a viral value of â¥50 copies/mL.</footnote>
                                    </content>
                                 </td>
                                 <td styleCode="Rrule">1%</td>
                                 <td styleCode="Rrule">0%</td>
                                 <td styleCode="Rrule">1%</td>
                                 <td styleCode="Rrule">1%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">No Virologic Data at Week 48 Window</content>
                                 </td>
                                 <td styleCode="Rrule">6%</td>
                                 <td styleCode="Rrule">6%</td>
                                 <td styleCode="Rrule">9%</td>
                                 <td styleCode="Rrule">7%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Discontinued Study Drug Due to AE or Death and Last Available HIV-1 RNA &lt;50 copies/mL</td>
                                 <td styleCode="Rrule">2%</td>
                                 <td styleCode="Rrule">1%</td>
                                 <td styleCode="Rrule">3%</td>
                                 <td styleCode="Rrule">1%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Discontinued Study Drug Due to Other Reasons and Last Available HIV-1 RNA &lt;50 copies/mL<footnote ID="K7738">Includes participants who discontinued for reasons other than an AE, death, or lack or loss of efficacy; e.g., withdrew consent, loss to follow-up, etc.</footnote>
                                 </td>
                                 <td styleCode="Rrule">4%</td>
                                 <td styleCode="Rrule">4%</td>
                                 <td styleCode="Rrule">5%</td>
                                 <td styleCode="Rrule">5%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Missing Data During Window but on Study Drug</td>
                                 <td styleCode="Rrule">&lt;1%</td>
                                 <td styleCode="Rrule">1%</td>
                                 <td styleCode="Rrule">1%</td>
                                 <td styleCode="Rrule">1%</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="f856afa8-1543-4d5b-a5ca-b2e3989840f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2	Clinical Trial Results for Adult Participants with no Antiretroviral Treatment History and Adults with Renal Impairment for Components of ODEFSEY</title>
                     <text>
                        <paragraph>The efficacy of RPV, FTC, and TAF in the treatment of HIV-1 infection in adults as initial therapy in those with no antiretroviral treatment history <content styleCode="italics">[see <linkHtml href="#S1">Indications and Usage (1)</linkHtml>]</content> was established in trials of:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>RPV+FTC/TDF in adults with HIV-1 as initial therapy in those with no antiretroviral treatment history (n=550). The virologic response rate (i.e., HIV-1 RNA less than 50 copies per mL) was 77% at Week 96. The virologic response rate at 96 weeks was 83% in participants with baseline HIV-1 RNA less than or equal to 100,000 copies per mL and 71% in participants with baseline HIV-1 RNA greater than 100,000 copies per mL.  Further, the virologic response rate at 96 weeks among participants with baseline CD4+ cell counts less than 200 and greater than or equal to 200 cells/mm<sup>3</sup> were 68% and 82%, respectively.</item>
                           <item>FTC+TAF with EVG+COBI in adults with HIV-1 as initial therapy in those with no antiretroviral treatment history (n=866). The virologic response rate (i.e., HIV-1 RNA less than 50 copies per mL) was 92% at Week 48.</item>
                        </list>
                        <paragraph>In the clinical trial of 248 adults with HIV-1 and estimated creatinine clearance greater than 30 mL per minute but less than 70 mL per minute, 95% (235/248) of the combined populations of treatment-naÃ¯ve (N=6) begun on FTC+TAF with EVG+COBI and those previously virologically-suppressed on other regimens (N=242) and switched to FTC+TAF with EVG +COBI had HIV-1 RNA levels less than 50 copies per mL at Week 24.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.3">
                     <id root="2c09715d-4795-4ab1-a227-e8a9fc5a934d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3	Clinical Trial Results for Pediatric Participants Aged 6 to Less than 18 Years Old for Components of ODEFSEY</title>
                     <text>
                        <paragraph>The efficacy of RPV, FTC, and TAF in the treatment of HIV-1 infection in pediatric patients aged 6 to less than 18 years old and greater than 25 kg as initial therapy in those with no antiretroviral treatment history and to replace a stable antiretroviral regimen in those who are virologically-suppressed <content styleCode="italics">[see <linkHtml href="#S1">Indications and Usage (1)</linkHtml>]</content> was established in trials of pediatric participants with HIV-1 aged 6 to less than 18 years with:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>RPV in combination with other antiretroviral agents in 36 treatment-naÃ¯ve adolescents with HIV-1 weighing at least 32 kg. The majority of participants (24/36) received RPV in combination with FTC and TDF. Of these 24 participants, 20 had a baseline HIV-1 RNA less than or equal to 100,000 copies per mL. The virologic response rate in these 20 participants (i.e., HIV-1 RNA less than 50 copies per mL) was 80% (16/20) at 48 weeks.</item>
                           <item>RPV in combination with other antiretroviral agents (two NRTIs) in 18 treatment-naÃ¯ve pediatric participants with HIV-1 weighing at least 17 kg (median [range]: 25 kg [17â51 kg]). The virologic response rate (i.e., HIV-1 RNA less than 50 copies per mL) was 72% (13/18) at 48 weeks.</item>
                           <item>RPV in combination with other antiretrovirals in 26 virologically-suppressed pediatric participants with HIV-1 less than 12 years old weighing at least 16 kg (N=26) at 48-week.</item>
                           <item>FTC+TAF with EVG+COBI in 50 treatment-naÃ¯ve adolescents with HIV-1 aged 12 to less than 18 years weighing at least 35 kg. The virologic response rate (i.e., HIV-1 RNA less than 50 copies per mL) was 92% (46/50) at 48 weeks.</item>
                           <item>FTC+TAF with EVG+COBI in 52 virologically-suppressed pediatric participants with HIV-1 aged 6 to less than 12 years weighing at least 25 kg. The virologic response rate (i.e., HIV-1 RNA less than 50 copies per mL) was 98% (51/52) at 48 weeks.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="73c81b69-8e0c-41d4-abba-87df9ea61b2f"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>ODEFSEY tablets are gray, capsule-shaped, and film coated with "GSI" debossed on one side and "255" on the other side. Each bottle contains 30 tablets (NDC 61958-2101-1), a silica gel desiccant, and a polyester coil, and is closed with a child-resistant closure.</paragraph>
               </text>
               <effectiveTime value="20250224"/>
               <component>
                  <section>
                     <id root="9f1f1500-04cb-4e70-bc67-210a72a42a45"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store below 30Â°C (86Â°F).</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Keep container tightly closed.</item>
                           <item>Dispense only in original container.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="85009e54-e0da-4819-a6bc-2a8955565197"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20250224"/>
               <component>
                  <section>
                     <id root="c2005e6f-a7a4-42cd-815f-bf4b9cec3290"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Post-treatment Acute Exacerbation of Hepatitis B in Patients with HBV Coinfection</content>
                        </paragraph>
                        <paragraph>Severe acute exacerbations of hepatitis B have been reported in patients with HBV and HIV-1 who have discontinued products containing FTC and/or TDF, and may likewise occur with discontinuation of ODEFSEY <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>. Advise the patient to not discontinue ODEFSEY without first informing their healthcare provider.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="92a4ca5e-264c-41dd-878e-567bb8b99b25"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Severe Skin Reactions and Hypersensitivity</content>
                        </paragraph>
                        <paragraph>Inform patients that skin reactions ranging from mild to severe, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported with RPV-containing products. Instruct patients to immediately stop taking ODEFSEY and seek medical attention if they develop a rash associated with any of the following symptoms: fever, blisters, mucosal involvement, eye inflammation (conjunctivitis), severe allergic reaction causing swelling of the face, eyes, lips, mouth, tongue or throat which may lead to difficulty swallowing or breathing, and any signs and symptoms of liver problems, as they may be a sign of a more serious reaction. Patients should understand that if severe rash occurs, they will be closely monitored, laboratory tests will be performed and appropriate therapy will be initiated <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="6447a1b6-56c6-4fe5-b7a9-7324f300323e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hepatotoxicity</content>
                        </paragraph>
                        <paragraph>Inform patients that hepatotoxicity has been reported with RPV, therefore, it is important to inform the healthcare professional if patients have underlying hepatitis B or C or elevations in liver-associated tests prior to treatment <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml> and <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="bf01c3ba-6563-431d-88ec-e690a8569661"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Depressive Disorders</content>
                        </paragraph>
                        <paragraph>Inform patients that depressive disorders (depressed mood, depression, dysphoria, major depression, mood altered, negative thoughts, suicide attempt, suicidal ideation) have been reported with RPV. Inform patients to seek immediate medical evaluation if they experience depressive symptoms <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7d2b9a38-0809-41ab-a80b-f8966e245db4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">New Onset or Worsening Renal Impairment</content>
                        </paragraph>
                        <paragraph>Advise patients to avoid taking ODEFSEY with concurrent or recent use of nephrotoxic agents. Postmarketing cases of renal impairment, including acute renal failure, have been reported <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="bb75d4ef-e470-4a67-8c62-8c5e6f06b990"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>ODEFSEY may interact with many drugs and is not recommended to be coadministered with numerous drugs. Advise patients to report to their healthcare provider the use of any other prescription or nonprescription medication or herbal products, including St. John's wort <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml> and <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0a67f575-1084-4b69-86ee-8ea71e58eb53"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactic Acidosis and Severe Hepatomegaly</content>
                        </paragraph>
                        <paragraph>Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with use of drugs similar to ODEFSEY. Advise patients to stop taking ODEFSEY if they develop clinical symptoms suggestive of lactic acidosis or pronounced hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="311d397d-1511-4596-b3e3-e167502c0811"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Immune Reconstitution Syndrome</content>
                        </paragraph>
                        <paragraph>Advise patients to inform their healthcare provider immediately of any symptoms of infection, as in some patients with advanced HIV infection (AIDS), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="4c595307-0bad-4dbe-bca3-a6e25799dfd8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Missed Dosage</content>
                        </paragraph>
                        <paragraph>Inform patients that it is important to take ODEFSEY on a regular dosing schedule with a meal and to avoid missing doses, as it can result in development of resistance <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f04eaef2-96c7-422c-93b1-a79cfff54d3d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Registry</content>
                        </paragraph>
                        <paragraph>Inform patients that there is an antiretroviral pregnancy registry to monitor fetal outcomes in those exposed to ODEFSEY during pregnancy  <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f697f1fc-9e13-45d7-b922-f7a693c2d15e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Instruct patients with HIV-1 that the potential risks of breastfeeding include: (1) HIV-1 transmission to infants without HIV-1, (2) developing viral resistance in infants with HIV-1, and (3) adverse reactions in a breastfed infant similar to those seen in adults <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="e4517d04-326a-4d8d-9f55-fbbdd128453c"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>ODEFSEY is a trademark of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners. </paragraph>
               </text>
               <effectiveTime value="20250224"/>
            </section>
         </component>
         <component>
            <section>
               <id root="e7ceded7-afd4-4362-847c-dfad6f22f456"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="3%" align="left" valign="top"/>
                     <col width="27%" align="left" valign="top"/>
                     <col width="60%" align="left" valign="top"/>
                     <col width="10%" align="right" valign="top"/>
                     <thead>
                        <tr>
                           <th colspan="4" align="center" styleCode="Lrule Rrule" valign="top">Patient Information <br/>ODEFSEY<sup>Â®</sup> (oh-DEF-see) <br/>(emtricitabine, rilpivirine and tenofovir alafenamide) <br/>tablets</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td colspan="3">This Patient Information has been approved by the U.S. Food and Drug Administration</td>
                           <td align="left">Revised: 02/2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Important: Ask your healthcare provider or pharmacist about medicines that should not be taken with ODEFSEY.</content> For more information, see "<linkHtml href="#whatshould">What should I tell my healthcare provider before taking ODEFSEY?</linkHtml>"</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold" ID="Whatis">What is the most important information I should know about ODEFSEY?<br/>ODEFSEY can cause serious side effects, including: </content>
                              <list>
                                 <item>
                                    <content styleCode="bold">Worsening of hepatitis B virus (HBV) infection. Your healthcare provider will test you for HBV before or when you start treatment with ODEFSEY. If you have HBV and take ODEFSEY, your HBV may get worse (flare-up) if you stop taking ODEFSEY. A "flare-up" is when your HBV suddenly returns in a worse way than before. </content>
                                    <list listType="unordered" styleCode="disc">
                                       <item>Do not run out of ODEFSEY. Refill your prescription or talk to your healthcare provider before your ODEFSEY is all gone.</item>
                                       <item>Do not stop taking ODEFSEY without first talking to your healthcare provider.  </item>
                                       <item>If you stop taking ODEFSEY, your healthcare provider will need to check your health often and do blood tests regularly for several months to check your liver, and may give you a medicine to treat hepatitis B. Tell your healthcare provider about any new or unusual symptoms you may have after you stop taking ODEFSEY.</item>
                                    </list>
                                 </item>
                              </list>
                              <content styleCode="bold">For more information about side effects, see "<linkHtml href="#Whatare">What are the possible side effects of ODEFSEY?</linkHtml>"</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is ODEFSEY?</content>
                              <br/>ODEFSEY is a prescription medicine that is used to treat human immunodeficiency virus-1 (HIV-1) infection in adults and children who weigh at least 55 pounds (25 kg):<list listType="unordered">
                                 <item>who have not received HIV-1 medicines in the past and who have an amount of HIV-1 in their blood (this is called "viral load") that is no more than 100,000 copies/mL, <content styleCode="bold">or</content>
                                 </item>
                                 <item>to replace their current HIV-1 medicines for people whose healthcare provider determines that they meet certain requirements.</item>
                              </list>HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS). <br/>ODEFSEY contains the prescription medicines emtricitabine, rilpivirine and tenofovir alafenamide.<br/>It is not known if ODEFSEY is safe and effective in children who weigh less than 55 pounds (25 kg).</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Who should not take ODEFSEY?<br/>Do not take ODEFSEY if you also take a medicine that contains:</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Lrule">
                              <list listType="unordered">
                                 <item>carbamazepine</item>
                                 <item>dexamethasone</item>
                                 <item>dexlansoprazole</item>
                                 <item>esomeprazole</item>
                                 <item>lansoprazole</item>
                                 <item>omeprazole</item>
                                 <item>oxcarbazepine </item>
                                 <item>pantoprazole sodium</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list listType="unordered">
                                 <item>phenobarbital</item>
                                 <item>phenytoin</item>
                                 <item>rabeprazole</item>
                                 <item>rifampin</item>
                                 <item>rifapentine</item>
                                 <item>St. John's wort (<content styleCode="italics">Hypericum perforatum</content>) or a product that contains St. John's wort</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold" ID="whatshould">What should I tell my healthcare provider before taking ODEFSEY?<br/>Before taking ODEFSEY, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list listType="unordered">
                                 <item>have liver problems, including HBV or hepatitis C virus</item>
                                 <item>have kidney problems</item>
                                 <item>have a history of depression or suicidal thoughts</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if ODEFSEY can harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with ODEFSEY.<br/>
                                    <content styleCode="bold">Pregnancy Registry:</content> There is a pregnancy registry for those who take ODEFSEY during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk with your healthcare provider about how you can take part in this registry.</item>
                                 <item>are breastfeeding or plan to breastfeed.<list listType="unordered" styleCode="disc">
                                       <item>Two of the medicines in ODEFSEY can pass to your baby in your breast milk. It is not known if the other medicine in ODEFSEY can pass into your breast milk.</item>
                                       <item>Talk to your healthcare provider about the  following risks of breastfeeding during treatment with ODEFSEY: 													<list listType="unordered" styleCode="disc">
                                             <item>The HIV-1 virus may pass to your baby if your baby does not have HIV-1.</item>
                                             <item>The HIV-1 virus may become harder to treat if your baby has HIV-1.</item>
                                             <item>Your baby may get side effects from ODEFSEY.</item>
                                          </list>
                                       </item>
                                    </list>
                                 </item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. <br/>Some medicines may interact with ODEFSEY. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.<list listType="unordered">
                                 <item>You can ask your healthcare provider or pharmacist for a list of medicines that interact with ODEFSEY.</item>
                                 <item>
                                    <content styleCode="bold">Do not start a new medicine without telling your healthcare provider.</content> Your healthcare provider can tell you if it is safe to take ODEFSEY with other medicines.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I take ODEFSEY?</content>
                              <list listType="unordered">
                                 <item>Take ODEFSEY exactly as your healthcare provider tells you to take it. ODEFSEY is taken by itself (not with other HIV-1 medicines) to treat HIV-1 infection. </item>
                                 <item>Take ODEFSEY 1 time each day with a meal. </item>
                                 <item>If you are on dialysis, take your daily dose of ODEFSEY following dialysis.</item>
                                 <item>Do not change your dose or stop taking ODEFSEY without first talking with your healthcare provider. Stay under a healthcare provider's care during treatment with ODEFSEY.</item>
                                 <item>Do not miss a dose of ODEFSEY. </item>
                                 <item>When your ODEFSEY supply starts to run low, get more from your healthcare provider or pharmacy. This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. The virus may develop resistance to ODEFSEY and become harder to treat.</item>
                                 <item>If you take too much ODEFSEY, call your healthcare provider or go to the nearest hospital emergency room right away. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold" ID="Whatare">What are the possible side effects of ODEFSEY?<br/>ODEFSEY may cause serious side effects, including:</content>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">See "<linkHtml href="#Whatis">What is the most important information I should know about ODEFSEY?</linkHtml>"</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Severe skin rash and allergic reactions.</content> Skin rash is a common side effect of ODEFSEY. Rash can be serious. Call your healthcare provider right away if you get a rash. In some cases, rash and allergic reaction may need to be treated in a hospital.<br/>
                                    <content styleCode="bold">If you get a rash with any of the following symptoms, stop taking ODEFSEY and call your healthcare provider or get medical help right away:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered">
                                 <item>fever</item>
                                 <item>skin blisters</item>
                                 <item>mouth sores</item>
                                 <item>redness or swelling of the eyes (conjunctivitis)</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list listType="unordered">
                                 <item>swelling of the face, lips, mouth, or throat</item>
                                 <item>trouble breathing or swallowing</item>
                                 <item>pain on the right side of the stomach (abdominal) area</item>
                                 <item>dark "tea colored" urine</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Change in liver enzymes.</content> People with a history of hepatitis B or C virus or who have certain liver enzyme changes may have an increased risk of developing new or worsening liver problems during treatment with ODEFSEY. Liver problems can also happen during treatment with ODEFSEY in people without a history of liver disease. Your healthcare provider may need to do tests to check your liver enzymes before and during treatment with ODEFSEY. </item>
                                 <item>
                                    <content styleCode="bold">Depression or mood changes. Tell your healthcare provider right away if you have any of the following symptoms:</content>
                                    <list listType="unordered" styleCode="disc">
                                       <item>feel sad or hopeless</item>
                                       <item>feel anxious or restless</item>
                                       <item>have thoughts of hurting yourself (suicide) or have tried to hurt yourself</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">New or worse kidney problems, including kidney failure.</content> Your healthcare provider should do blood and urine tests to check your kidneys before you start and during treatment with ODEFSEY. Your healthcare provider may tell you to stop taking ODEFSEY if you develop new or worse kidney problems.</item>
                                 <item>
                                    <content styleCode="bold">Too much lactic acid in your blood (lactic acidosis)</content>. Too much lactic acid is a serious but rare medical emergency that can lead to death.  <content styleCode="bold">Tell your healthcare provider right away if you get these symptoms:</content> weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat. </item>
                                 <item>
                                    <content styleCode="bold">Severe liver problems</content>.  In rare cases, severe liver problems can happen that can lead to death<content styleCode="bold">. Tell your healthcare provider right away if you get these symptoms:</content> skin or the white part of your eyes turns yellow, dark "tea-colored" urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.</item>
                                 <item>
                                    <content styleCode="bold">Changes in your immune system (Immune Reconstitution Syndrome)</content> can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having any new symptoms after starting your HIV-1 medicine.</item>
                              </list>
                              <content styleCode="bold">The most common side effects of ODEFSEY are</content> headache and problems sleeping<content styleCode="bold">.</content>
                              <br/>These are not all of the possible side effects of ODEFSEY. <br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store ODEFSEY?</content>
                              <list listType="unordered">
                                 <item>Store ODEFSEY below 86Â°F (30Â°C).</item>
                                 <item>Keep ODEFSEY in its original container. </item>
                                 <item>Keep the container tightly closed.</item>
                              </list>
                              <content styleCode="bold">Keep ODEFSEY and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of ODEFSEY.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ODEFSEY for a condition for which it was not prescribed. Do not give ODEFSEY to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about ODEFSEY that is written for health professionals.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in ODEFSEY?</content>
                              <br/>
                              <content styleCode="bold">Active ingredients:</content> emtricitabine, rilpivirine, and tenofovir alafenamide.<br/>
                              <content styleCode="bold">Inactive ingredients:</content> croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polysorbate 20, and povidone. The tablet film coating contains iron oxide black, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.<br/>Manufactured and distributed by: Gilead Sciences, Inc. Foster City, CA 94404<br/>ODEFSEY is a trademark of Gilead Sciences, Inc., or its related companies.<br/>Â© 2025 Gilead Sciences, Inc. All rights reserved. 208351-GS-007<br/>         For more information, call 1-800-445-3235 or go to www.ODEFSEY.com.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250224"/>
            </section>
         </component>
         <component>
            <section ID="id_link_b68a5d56-1a0b-755c-e053-2995a90a3954">
               <id root="826dcb63-a9d6-4470-8055-c836c08b672c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 30 Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 61958- <content styleCode="bold">2101</content>-1<br/>
                     <br/>
                     <content styleCode="bold">30 tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Odefsey <sup>Â®</sup>
                        <br/>
                        <br/>(emtricitabine, rilpivirine, and<br/>
                        <br/>tenofovir alafenamide) Tablets<br/>
                        <br/>200 mg/25 mg/25 mg </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Note to pharmacist:<br/>
                        <br/>Do not cover ALERT box with pharmacy label. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ALERT: Find out about medicines that<br/>
                        <br/>should NOT be taken with Odefsey <sup>Â®</sup>
                     </content>
                     <renderMultiMedia referencedObject="img_b68a57f0-9c78-76b8-e053-2995a90a0b0b"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250224"/>
               <component>
                  <observationMedia ID="img_b68a57f0-9c78-76b8-e053-2995a90a0b0b">
                     <text>odefsey-04.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="odefsey-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>